CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | antipsychotic agent |
|
Accession: | CHEBI:35476
|
browse the term
|
Definition: | Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. |
Synonyms: | related_synonym: | Neuroleptikum; antipsychotic agents; antipsychotic drug; antipsychotic drugs; antipsychotics; antipsychotiques; grosser Tranquilizer; major tranquilizers; major tranquilizing agents; neuroleptic; neuroleptic agents; neuroleptics; neuroleptique; neuroleptiques |
|
|
|
G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A |
multiple interactions |
ISO |
Chlorprothixene inhibits the reaction [(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane binds to HTR1A protein] |
CTD |
PMID:2891550 |
|
NCBI chr13:105,580,040...105,584,630
Ensembl chr13:105,580,147...105,584,630
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases activity |
ISO |
Chlorprothixene results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Prl |
prolactin |
increases secretion |
ISO |
Chlorprothixene results in increased secretion of PRL protein |
CTD |
PMID:10525070 |
|
NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188
|
|
|
G |
Ache |
acetylcholinesterase |
increases activity |
EXP |
Acepromazine results in increased activity of ACHE protein |
CTD |
PMID:29614332 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
acetophenazine binds to and results in decreased activity of AR protein |
CTD |
PMID:17606915 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Amisulpride results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Drd2 |
dopamine receptor D2 |
affects binding |
ISO |
Amisulpride binds to DRD2 protein |
CTD |
PMID:12191584 |
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Prl |
prolactin |
increases expression increases secretion multiple interactions |
ISO |
Amisulpride results in increased expression of PRL protein Amisulpride results in increased secretion of PRL protein Bromocriptine inhibits the reaction [Amisulpride results in increased secretion of PRL protein]; carmoxirole inhibits the reaction [Amisulpride results in increased secretion of PRL protein] |
CTD |
PMID:12106810 PMID:14966260 PMID:14997280 PMID:15665803 PMID:16938372 PMID:18063941 More...
|
|
NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188
|
|
G |
Vipr2 |
vasoactive intestinal peptide receptor 2 |
decreases expression |
ISO |
Amisulpride results in decreased expression of VIPR2 mRNA |
CTD |
PMID:27900577 |
|
NCBI chr12:116,041,040...116,117,842
Ensembl chr12:116,041,346...116,109,881
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
multiple interactions |
ISO |
amperozide inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:19583963 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
|
G |
Acadl |
acyl-Coenzyme A dehydrogenase, long-chain |
decreases expression |
ISO |
Aripiprazole results in decreased expression of ACADL mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 1:66,869,998...66,902,468
Ensembl chr 1:66,869,998...66,902,436
|
|
G |
Adora2a |
adenosine A2a receptor |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of ADORA2A mRNA |
CTD |
PMID:31476115 |
|
NCBI chr10:75,152,711...75,170,626
Ensembl chr10:75,152,711...75,170,618
|
|
G |
Arpc1b |
actin related protein 2/3 complex, subunit 1B |
decreases expression |
ISO |
Aripiprazole results in decreased expression of ARPC1B mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 5:145,051,066...145,064,996
Ensembl chr 5:145,051,025...145,067,515
|
|
G |
Bcl10 |
B cell leukemia/lymphoma 10 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of BCL10 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 3:145,630,017...145,640,121
Ensembl chr 3:145,628,559...145,640,111
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bcl6 |
B cell leukemia/lymphoma 6 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of BCL6 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr16:23,780,058...23,807,602
Ensembl chr16:23,783,802...23,807,602
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of BID mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
C1rb |
complement component 1, r subcomponent B |
multiple interactions |
ISO |
Aripiprazole promotes the reaction [Ozone results in decreased expression of C1R mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr 6:124,547,389...124,558,003
Ensembl chr 6:124,547,253...124,558,130
|
|
G |
C2 |
complement component 2 (within H-2S) |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of C2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr17:35,081,578...35,101,076
Ensembl chr17:35,081,580...35,117,241
|
|
G |
Cbx7 |
chromobox 7 |
decreases expression increases expression |
ISO |
Aripiprazole results in decreased expression of CBX7 mRNA Aripiprazole results in increased expression of CBX7 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr15:79,800,005...79,855,344
Ensembl chr15:79,800,008...79,855,320
|
|
G |
Ccl19 |
chemokine (C-C motif) ligand 19 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CCL19 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 4:42,754,525...42,756,558
Ensembl chr 4:42,754,525...42,756,577
|
|
G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CCL2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl20 |
chemokine (C-C motif) ligand 20 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CCL20 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:83,094,487...83,096,888
Ensembl chr 1:83,094,487...83,096,888
|
|
G |
Ccl22 |
chemokine (C-C motif) ligand 22 |
multiple interactions |
ISO |
Aripiprazole inhibits the reaction [Ozone results in increased expression of CCL22 mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr 8:95,472,312...95,478,016
Ensembl chr 8:95,472,218...95,478,327
|
|
G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CCL3 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccl4 |
chemokine (C-C motif) ligand 4 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CCL4 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509
|
|
G |
Ccl5 |
chemokine (C-C motif) ligand 5 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CCL5 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr11:83,416,604...83,421,344
Ensembl chr11:83,416,604...83,421,344
|
|
G |
Ccr3 |
chemokine (C-C motif) receptor 3 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CCR3 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 9:123,817,799...123,831,729
Ensembl chr 9:123,822,009...123,831,726
|
|
G |
Cd274 |
CD274 antigen |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CD274 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr19:29,339,428...29,365,495
Ensembl chr19:29,344,855...29,365,495
|
|
G |
Cd33 |
CD33 molecule |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CD33 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 7:43,176,823...43,186,679
Ensembl chr 7:43,173,640...43,193,852
|
|
G |
Cd44 |
CD44 antigen |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CD44 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cd70 |
CD70 antigen |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CD70 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr17:57,452,997...57,456,777
Ensembl chr17:57,452,997...57,456,777
|
|
G |
Cd83 |
CD83 antigen |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CD83 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr13:43,938,588...43,956,609
Ensembl chr13:43,938,251...43,956,608
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
ISO |
Aripiprazole inhibits the reaction [Ozone results in increased expression of CDH5 mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr 8:104,828,247...104,871,136
Ensembl chr 8:104,828,257...104,871,143
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A (P21) |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CDKN1A mRNA |
CTD |
PMID:31476115 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cebpb |
CCAAT/enhancer binding protein (C/EBP), beta |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CEBPB mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
ISO EXP |
Aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of 4-nitrophenyl acetate]; Aripiprazole inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate] |
CTD |
PMID:20097249 |
|
NCBI chr 8:93,892,700...93,924,432
Ensembl chr 8:93,892,696...93,924,466
|
|
G |
Cfb |
complement factor B |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CFB mRNA |
CTD |
PMID:31476115 |
|
NCBI chr17:35,075,350...35,081,492
Ensembl chr17:35,075,350...35,081,494
|
|
G |
Cldn5 |
claudin 5 |
decreases expression |
ISO |
Aripiprazole results in decreased expression of CLDN5 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr16:18,595,597...18,597,012
Ensembl chr16:18,595,597...18,597,012
|
|
G |
Cnr1 |
cannabinoid receptor 1 (brain) |
increases expression |
ISO |
Aripiprazole results in increased expression of CNR1 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
Aripiprazole results in increased expression of COMT mRNA |
CTD |
PMID:17868501 |
|
NCBI chr16:18,225,632...18,247,006
Ensembl chr16:18,225,636...18,245,602
|
|
G |
Creb5 |
cAMP responsive element binding protein 5 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CREB5 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 6:53,264,154...53,677,349
Ensembl chr 6:53,264,255...53,677,361
|
|
G |
Crebbp |
CREB binding protein |
decreases expression |
ISO |
Aripiprazole results in decreased expression of CREBBP mRNA |
CTD |
PMID:17868501 |
|
NCBI chr16:3,899,198...4,031,864
Ensembl chr16:3,899,192...4,031,861
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
increases expression |
ISO |
Aripiprazole results in increased expression of CRMP1 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 5:37,399,402...37,449,507
Ensembl chr 5:37,399,284...37,449,477
|
|
G |
Csf1 |
colony stimulating factor 1 (macrophage) |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CSF1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785
|
|
G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CSF2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
|
|
G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CSF3 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455
|
|
G |
Cx3cl1 |
chemokine (C-X3-C motif) ligand 1 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CX3CL1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 8:95,498,808...95,509,055
Ensembl chr 8:95,498,637...95,509,055
|
|
G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CXCL1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
|
|
G |
Cxcl15 |
chemokine (C-X-C motif) ligand 15 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CXCL8 mRNA; [Aripiprazole co-treated with Ozone] results in increased secretion of CXCL8 protein; Aripiprazole promotes the reaction [Ozone results in increased expression of CXCL8 mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CXCL2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cxcl3 |
chemokine (C-X-C motif) ligand 3 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CXCL1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cxcr5 |
chemokine (C-X-C motif) receptor 5 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CXCR5 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 9:44,423,084...44,437,741
Ensembl chr 9:44,423,084...44,473,174
|
|
G |
Cxcr6 |
chemokine (C-X-C motif) receptor 6 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CXCR6 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 9:123,635,542...123,640,819
Ensembl chr 9:123,635,540...123,640,825
|
|
G |
Cybb |
cytochrome b-245, beta polypeptide |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CYBB mRNA |
CTD |
PMID:31476115 |
|
NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010
|
|
G |
Cyld |
CYLD lysine 63 deubiquitinase |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of CYLD mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 8:89,423,506...89,478,574
Ensembl chr 8:89,423,656...89,478,573
|
|
G |
Ddr2 |
discoidin domain receptor family, member 2 |
decreases expression |
ISO |
Aripiprazole results in decreased expression of DDR2 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 1:169,799,874...169,938,525
Ensembl chr 1:169,799,876...169,938,331
|
|
G |
Ddx50 |
DExD box helicase 50 |
increases expression |
ISO |
Aripiprazole results in increased expression of DDX50 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr10:62,451,571...62,487,260
Ensembl chr10:62,451,674...62,486,997
|
|
G |
Dnal4 |
dynein, axonemal, light chain 4 |
decreases expression |
ISO |
Aripiprazole results in decreased expression of DNAL4 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr15:79,645,654...79,658,649
Ensembl chr15:79,645,654...79,662,050
|
|
G |
Dnmt3a |
DNA methyltransferase 3A |
increases expression |
ISO |
Aripiprazole results in increased expression of DNMT3A mRNA |
CTD |
PMID:17868501 |
|
NCBI chr12:3,851,559...3,964,443
Ensembl chr12:3,856,007...3,964,443
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
[Aripiprazole binds to and results in increased activity of DRD2 protein] which results in increased susceptibility to Methamphetamine |
CTD |
PMID:17069544 PMID:17327886 |
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of DUSP4 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 8:35,274,448...35,289,106
Ensembl chr 8:35,274,451...35,287,048
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of DUSP6 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr10:99,098,676...99,103,351
Ensembl chr10:99,099,093...99,103,351
|
|
G |
Ebi3 |
Epstein-Barr virus induced gene 3 |
multiple interactions |
ISO |
Aripiprazole promotes the reaction [Ozone results in increased expression of EBI3 mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr17:56,259,623...56,264,022
Ensembl chr17:56,259,640...56,264,022
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Aripiprazole results in increased expression of EGR1 mRNA; Aripiprazole results in increased expression of EGR1 protein |
CTD |
PMID:17868501 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
Aripiprazole results in increased expression of EGR2 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr10:67,370,334...67,383,354
Ensembl chr10:67,371,305...67,378,018
|
|
G |
Egr4 |
early growth response 4 |
increases expression |
ISO |
Aripiprazole results in increased expression of EGR4 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 6:85,488,103...85,490,571
Ensembl chr 6:85,488,103...85,490,571
|
|
G |
Elane |
elastase, neutrophil expressed |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of ELANE mRNA |
CTD |
PMID:31476115 |
|
NCBI chr10:79,722,146...79,724,050
Ensembl chr10:79,722,081...79,724,049
|
|
G |
Elavl2 |
ELAV like RNA binding protein 1 |
increases expression |
ISO |
Aripiprazole results in increased expression of ELAVL2 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 4:91,099,770...91,288,407
Ensembl chr 4:91,139,000...91,289,022
|
|
G |
Ets1 |
E26 avian leukemia oncogene 1, 5' domain |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of ETS1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 9:32,547,501...32,669,116
Ensembl chr 9:32,547,517...32,669,116
|
|
G |
Exoc2 |
exocyst complex component 2 |
increases expression |
ISO |
Aripiprazole results in increased expression of EXOC2 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr13:30,972,939...31,162,082
Ensembl chr13:30,997,902...31,158,076
|
|
G |
F2rl1 |
coagulation factor II (thrombin) receptor-like 1 |
multiple interactions |
ISO |
Aripiprazole inhibits the reaction [Ozone results in increased expression of F2RL1 mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr13:95,648,226...95,661,748
Ensembl chr13:95,648,240...95,661,735
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 (zygin I) |
multiple interactions increases expression |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of FEZ1 mRNA Aripiprazole results in increased expression of FEZ1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 9:36,732,694...36,790,222
Ensembl chr 9:36,733,160...36,790,220
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
Aripiprazole results in decreased expression of FN1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
decreases expression |
ISO |
Aripiprazole results in decreased expression of HBEGF mRNA |
CTD |
PMID:17868501 |
|
NCBI chr18:36,637,980...36,648,858
Ensembl chr18:36,637,980...36,648,858
|
|
G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A |
multiple interactions |
ISO |
Aripiprazole binds to and affects the activity of HTR1A protein; Aripiprazole binds to and results in increased activity of HTR1A protein |
CTD |
PMID:17069544 PMID:21823597 |
|
NCBI chr13:105,580,040...105,584,630
Ensembl chr13:105,580,147...105,584,630
|
|
G |
Htr2a |
5-hydroxytryptamine (serotonin) receptor 2A |
multiple interactions decreases response to substance affects response to substance |
ISO |
Aripiprazole binds to and results in decreased activity of HTR2A protein; Aripiprazole binds to and results in increased activity of HTR2A protein; Aripiprazole inhibits the reaction [Ketanserin binds to HTR2A protein] HTR2A gene SNP results in decreased susceptibility to Aripiprazole HTR2A protein affects the susceptibility to Aripiprazole |
CTD |
PMID:16314884 PMID:21823597 |
|
NCBI chr14:74,878,314...74,944,299
Ensembl chr14:74,878,280...74,946,934
|
|
G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C |
multiple interactions |
ISO |
Aripiprazole binds to and affects the activity of HTR2C protein |
CTD |
PMID:21823597 |
|
NCBI chr X:145,745,509...145,980,273
Ensembl chr X:145,745,509...145,980,273
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of ICAM1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Icam4 |
intercellular adhesion molecule 4, Landsteiner-Wiener blood group |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of ICAM4 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 9:20,940,728...20,941,892
Ensembl chr 9:20,940,669...20,941,891
|
|
G |
Icosl |
icos ligand |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of ICOSLG mRNA |
CTD |
PMID:31476115 |
|
NCBI chr10:77,904,921...77,915,359
Ensembl chr10:77,905,136...77,919,747
|
|
G |
Ifnb1 |
interferon beta 1, fibroblast |
increases expression multiple interactions |
ISO |
Aripiprazole results in increased expression of IFNB1 mRNA Aripiprazole promotes the reaction [Ozone results in increased expression of IFNB1 mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr 4:88,440,253...88,441,083
Ensembl chr 4:88,440,262...88,441,011
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of IFNG mRNA |
CTD |
PMID:31476115 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Ifngr1 |
interferon gamma receptor 1 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IFNGR1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr10:19,467,697...19,485,977
Ensembl chr10:19,467,697...19,485,977
|
|
G |
Ikbke |
inhibitor of kappaB kinase epsilon |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IKBKE mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:131,182,337...131,207,339
Ensembl chr 1:131,182,080...131,207,344
|
|
G |
Il11 |
interleukin 11 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL11 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 7:4,775,372...4,785,877
Ensembl chr 7:4,775,372...4,785,858
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL1A mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL1B mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il1r2 |
interleukin 1 receptor, type II |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL1R2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:40,123,872...40,164,390
Ensembl chr 1:40,113,239...40,164,391
|
|
G |
Il1rap |
interleukin 1 receptor accessory protein |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL1RAP mRNA |
CTD |
PMID:31476115 |
|
NCBI chr16:26,400,259...26,548,878
Ensembl chr16:26,400,454...26,548,867
|
|
G |
Il1rapl2 |
interleukin 1 receptor accessory protein-like 2 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL1RAPL2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr X:136,471,503...137,749,826
Ensembl chr X:136,471,357...137,747,695
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL1RL1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:40,444,025...40,504,578
Ensembl chr 1:40,468,730...40,504,575
|
|
G |
Il23a |
interleukin 23, alpha subunit p19 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL23A mRNA |
CTD |
PMID:31476115 |
|
NCBI chr10:128,132,009...128,133,953
Ensembl chr10:128,132,008...128,134,621
|
|
G |
Il24 |
interleukin 24 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL24 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:130,809,801...130,815,153
Ensembl chr 1:130,809,811...130,815,191
|
|
G |
Il2rg |
interleukin 2 receptor, gamma chain |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of IL2RG mRNA |
CTD |
PMID:31476115 |
|
NCBI chr X:100,307,991...100,311,861
Ensembl chr X:100,307,984...100,311,861
|
|
G |
Il4ra |
interleukin 4 receptor, alpha |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL4R mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 7:125,151,443...125,178,646
Ensembl chr 7:125,151,292...125,178,646
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL5 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr11:53,611,621...53,615,930
Ensembl chr11:53,611,621...53,615,933
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL6 mRNA; Aripiprazole promotes the reaction [Ozone results in increased expression of IL6 mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Il7r |
interleukin 7 receptor |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of IL7R mRNA |
CTD |
PMID:31476115 |
|
NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262
|
|
G |
Inpp5d |
inositol polyphosphate-5-phosphatase D |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of INPP5D mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:87,548,034...87,648,232
Ensembl chr 1:87,548,034...87,648,229
|
|
G |
Irak2 |
interleukin-1 receptor-associated kinase 2 |
multiple interactions |
ISO |
Aripiprazole promotes the reaction [Ozone results in increased expression of IRAK2 mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr 6:113,615,428...113,671,987
Ensembl chr 6:113,615,428...113,671,987
|
|
G |
Irf8 |
interferon regulatory factor 8 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of IRF8 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 8:121,463,097...121,483,433
Ensembl chr 8:121,463,097...121,483,433
|
|
G |
Isg20 |
interferon-stimulated protein |
multiple interactions increases expression |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of ISG20 mRNA Aripiprazole results in increased expression of ISG20 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 7:78,561,136...78,570,144
Ensembl chr 7:78,563,172...78,570,144
|
|
G |
Itga2 |
integrin alpha 2 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of ITGA2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr13:114,969,617...115,068,636
Ensembl chr13:114,969,617...115,068,636
|
|
G |
Itga5 |
integrin alpha 5 (fibronectin receptor alpha) |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of ITGA5 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr15:103,252,713...103,275,218
Ensembl chr15:103,252,713...103,275,190
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
multiple interactions decreases activity |
ISO |
Aripiprazole inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Aripiprazole results in decreased activity of KCNH2 protein |
CTD |
PMID:21158687 PMID:28551711 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
increases expression |
ISO |
Aripiprazole results in increased expression of KCNJ3 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 2:55,301,814...55,488,157
Ensembl chr 2:55,325,982...55,488,157
|
|
G |
Lif |
leukemia inhibitory factor |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of LIF mRNA |
CTD |
PMID:31476115 |
|
NCBI chr11:4,207,587...4,222,514
Ensembl chr11:4,207,557...4,222,514
|
|
G |
Lrrn3 |
leucine rich repeat protein 3, neuronal |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of LRRN3 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr12:41,501,667...41,536,056
Ensembl chr12:41,501,667...41,536,430
|
|
G |
Lta |
lymphotoxin A |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of LTA mRNA |
CTD |
PMID:31476115 |
|
NCBI chr17:35,422,141...35,424,568
Ensembl chr17:35,422,141...35,424,327
|
|
G |
Ltb |
lymphotoxin B |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of LTB mRNA |
CTD |
PMID:31476115 |
|
NCBI chr17:35,413,483...35,415,281
Ensembl chr17:35,413,415...35,415,296
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of LYN mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 4:3,676,865...3,791,612
Ensembl chr 4:3,678,115...3,813,122
|
|
G |
Maob |
monoamine oxidase B |
increases expression |
ISO |
Aripiprazole results in increased expression of MAOB mRNA |
CTD |
PMID:17868501 |
|
NCBI chr X:16,575,520...16,683,605
Ensembl chr X:16,575,521...16,683,605
|
|
G |
Mapk6 |
mitogen-activated protein kinase 6 |
increases expression |
ISO |
Aripiprazole results in increased expression of MAPK6 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 9:75,294,064...75,317,303
Ensembl chr 9:75,276,344...75,317,287
|
|
G |
Mapkapk2 |
MAP kinase-activated protein kinase 2 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of MAPKAPK2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:130,981,437...131,025,580
Ensembl chr 1:130,981,437...131,025,563
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of NFKB1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkb2 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100 |
multiple interactions |
ISO |
Aripiprazole promotes the reaction [Ozone results in increased expression of NFKB2 mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr19:46,285,478...46,300,839
Ensembl chr19:46,292,759...46,300,824
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of NFKBIA mRNA |
CTD |
PMID:31476115 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of NLRP3 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nod2 |
nucleotide-binding oligomerization domain containing 2 |
increases expression multiple interactions |
ISO |
Aripiprazole results in increased expression of NOD2 mRNA [Aripiprazole co-treated with Ozone] results in increased expression of NOD2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 8:89,373,943...89,415,103
Ensembl chr 8:89,373,943...89,415,102
|
|
G |
Npdc1 |
neural proliferation, differentiation and control 1 |
decreases expression |
ISO |
Aripiprazole results in decreased expression of NPDC1 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 2:25,293,062...25,299,506
Ensembl chr 2:25,289,363...25,299,506
|
|
G |
Nt5e |
5' nucleotidase, ecto |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of NT5E mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 9:88,209,662...88,254,142
Ensembl chr 9:88,209,250...88,254,145
|
|
G |
Ntm |
neurotrimin |
decreases expression |
ISO |
Aripiprazole results in decreased expression of NTM mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 9:28,906,045...29,874,565
Ensembl chr 9:28,906,046...29,874,437
|
|
G |
Pdcd1lg2 |
programmed cell death 1 ligand 2 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of PDCD1LG2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr19:29,388,319...29,450,327
Ensembl chr19:29,388,319...29,448,561
|
|
G |
Pdgfc |
platelet-derived growth factor, C polypeptide |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of PDGFC mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 3:80,943,723...81,121,347
Ensembl chr 3:80,943,723...81,121,347
|
|
G |
Pdp1 |
pyruvate dehydrogenase phosphatase catalytic subunit 1 |
increases expression |
ISO |
Aripiprazole results in increased expression of PDP1 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 4:11,958,183...11,966,450
Ensembl chr 4:11,958,184...11,966,452
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of PLAU mRNA |
CTD |
PMID:31476115 |
|
NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of PLAUR mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 7:24,161,857...24,175,393
Ensembl chr 7:24,161,909...24,175,393
|
|
G |
Pou2f2 |
POU domain, class 2, transcription factor 2 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of POU2F2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 7:24,790,111...24,879,292
Ensembl chr 7:24,786,769...24,879,151
|
|
G |
Prg2 |
proteoglycan 2, bone marrow |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of PRG2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 2:84,810,805...84,813,977
Ensembl chr 2:84,810,805...84,813,976
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of PRKCD mRNA |
CTD |
PMID:31476115 |
|
NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167
|
|
G |
Prl |
prolactin |
multiple interactions increases secretion decreases secretion decreases expression |
ISO |
Aripiprazole inhibits the reaction [haloperidol decanoate results in increased expression of PRL protein]; Aripiprazole inhibits the reaction [Risperidone results in increased secretion of PRL protein] Aripiprazole results in increased secretion of PRL protein Aripiprazole results in decreased secretion of PRL protein Aripiprazole inhibits the reaction [talipexole results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Aripiprazole results in decreased secretion of PRL protein] Aripiprazole results in decreased expression of PRL protein |
CTD |
PMID:8613910 PMID:17873694 PMID:19230981 PMID:19519261 PMID:19653986 PMID:19906340 PMID:20814333 More...
|
|
NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188
|
|
G |
Prodh |
proline dehydrogenase |
decreases expression |
ISO |
Aripiprazole results in decreased expression of PRODH mRNA |
CTD |
PMID:17868501 |
|
NCBI chr16:17,889,590...17,907,148
Ensembl chr16:17,878,221...17,908,067
|
|
G |
Psmc6 |
proteasome (prosome, macropain) 26S subunit, ATPase, 6 |
increases expression |
ISO |
Aripiprazole results in increased expression of PSMC6 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr14:45,567,285...45,587,150
Ensembl chr14:45,567,245...45,587,162
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of PTGS2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of PYCARD mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
increases expression |
ISO |
Aripiprazole results in increased expression of RAB3A mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 8:71,207,258...71,211,276
Ensembl chr 8:71,207,328...71,211,323
|
|
G |
Rasd1 |
RAS, dexamethasone-induced 1 |
increases expression |
ISO |
Aripiprazole results in increased expression of RASD1 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr11:59,854,007...59,855,770
Ensembl chr11:59,854,007...59,855,770
|
|
G |
Relb |
avian reticuloendotheliosis viral (v-rel) oncogene related B |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of RELB mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 7:19,340,142...19,363,352
Ensembl chr 7:19,340,142...19,363,363
|
|
G |
Rigi |
RNA sensor RIG-I |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of RIGI mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 4:40,203,775...40,239,843
Ensembl chr 4:40,203,773...40,239,828
|
|
G |
Saa1 |
serum amyloid A 1 |
multiple interactions |
ISO |
Aripiprazole inhibits the reaction [Ozone results in increased expression of SAA1 mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr 7:46,389,921...46,392,404
Ensembl chr 7:46,389,921...46,392,404
|
|
G |
Sae1 |
SUMO1 activating enzyme subunit 1 |
increases expression |
ISO |
Aripiprazole results in increased expression of SAE1 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 7:16,054,161...16,121,821
Ensembl chr 7:16,054,159...16,121,731
|
|
G |
Sbno2 |
strawberry notch 2 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of SBNO2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr10:79,892,826...79,941,942
Ensembl chr10:79,892,826...79,941,405
|
|
G |
Serpinb2 |
serine (or cysteine) peptidase inhibitor, clade B, member 2 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of SERPINB2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:107,439,153...107,453,330
Ensembl chr 1:107,439,153...107,463,208
|
|
G |
Sh2b2 |
SH2B adaptor protein 2 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of SH2B2 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 5:136,247,002...136,275,452
Ensembl chr 5:136,247,001...136,275,410
|
|
G |
Slamf6 |
SLAM family member 6 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of SLAMF6 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:171,745,002...171,776,525
Ensembl chr 1:171,745,082...171,780,737
|
|
G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
affects binding |
ISO |
Aripiprazole binds to SLC6A4 protein |
CTD |
PMID:21823597 |
|
NCBI chr11:76,889,423...76,923,169
Ensembl chr11:76,889,429...76,923,166
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
decreases expression |
ISO |
Aripiprazole results in decreased expression of SLCO2B1 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 7:99,307,011...99,360,547
Ensembl chr 7:99,307,011...99,360,547
|
|
G |
Slit3 |
slit guidance ligand 3 |
increases expression |
ISO |
Aripiprazole results in increased expression of SLIT3 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr11:35,012,283...35,599,334
Ensembl chr11:35,012,051...35,599,334
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of SMAD3 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 9:63,554,048...63,665,276
Ensembl chr 9:63,554,049...63,665,276
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of SOCS1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr16:10,601,672...10,603,400
Ensembl chr16:10,600,104...10,603,400
|
|
G |
Syt17 |
synaptotagmin XVII |
multiple interactions decreases expression |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of SYT17 mRNA Aripiprazole results in decreased expression of SYT17 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 7:117,979,936...118,048,120
Ensembl chr 7:117,979,940...118,047,445
|
|
G |
Tab1 |
TGF-beta activated kinase 1/MAP3K7 binding protein 1 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of TAB1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr15:80,017,333...80,045,908
Ensembl chr15:80,017,328...80,045,908
|
|
G |
Tacr3 |
tachykinin receptor 3 |
decreases expression increases expression |
ISO |
Aripiprazole results in decreased expression of TACR3 mRNA Aripiprazole results in increased expression of TACR3 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 3:134,534,768...134,640,342
Ensembl chr 3:134,534,768...134,640,340
|
|
G |
Thbd |
thrombomodulin |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of THBD mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 2:148,246,391...148,250,108
Ensembl chr 2:148,246,386...148,250,108
|
|
G |
Thbs1 |
thrombospondin 1 |
multiple interactions |
ISO |
Aripiprazole inhibits the reaction [Ozone results in increased expression of THBS1 mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614
|
|
G |
Ticam1 |
TIR domain containing adaptor molecule 1 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of TICAM1 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr17:56,576,462...56,583,767
Ensembl chr17:56,576,319...56,583,786
|
|
G |
Tlr3 |
toll-like receptor 3 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of TLR3 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 8:45,848,702...45,864,112
Ensembl chr 8:45,848,702...45,864,117
|
|
G |
Tlr5 |
toll-like receptor 5 |
increases expression multiple interactions |
ISO |
Aripiprazole results in increased expression of TLR5 mRNA [Aripiprazole co-treated with Ozone] results in decreased expression of TLR5 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:182,782,317...182,804,010
Ensembl chr 1:182,782,353...182,804,010
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Aripiprazole promotes the reaction [Ozone results in increased expression of TNF mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfaip3 |
tumor necrosis factor, alpha-induced protein 3 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of TNFAIP3 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr10:18,876,658...18,891,158
Ensembl chr10:18,876,658...18,891,405
|
|
G |
Tnfrsf11b |
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
multiple interactions |
ISO |
Aripiprazole inhibits the reaction [Ozone results in increased expression of TNFRSF11B mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr15:54,114,014...54,141,700
Ensembl chr15:54,114,015...54,141,880
|
|
G |
Tnfrsf12a |
tumor necrosis factor receptor superfamily, member 12a |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of TNFRSF12A mRNA |
CTD |
PMID:31476115 |
|
NCBI chr17:23,894,419...23,896,423
Ensembl chr17:23,894,419...23,896,442
|
|
G |
Tnfrsf14 |
tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of TNFRSF14 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 4:155,002,944...155,013,077
Ensembl chr 4:155,006,390...155,013,020
|
|
G |
Tnfrsf1b |
tumor necrosis factor receptor superfamily, member 1b |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of TNFRSF1B mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 4:144,938,938...144,973,453
Ensembl chr 4:144,940,033...144,973,440
|
|
G |
Tnfrsf8 |
tumor necrosis factor receptor superfamily, member 8 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of TNFRSF8 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 4:144,993,702...145,041,734
Ensembl chr 4:144,993,707...145,041,734
|
|
G |
Tnfrsf9 |
tumor necrosis factor receptor superfamily, member 9 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 4:151,004,612...151,030,561
Ensembl chr 4:150,999,019...151,030,559
|
|
G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 3:27,371,226...27,393,814
Ensembl chr 3:27,371,177...27,396,576
|
|
G |
Tnfsf12 |
tumor necrosis factor (ligand) superfamily, member 12 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in decreased expression of TNFSF12 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr11:69,577,066...69,586,924
Ensembl chr11:69,577,076...69,586,675
|
|
G |
Tnfsf15 |
tumor necrosis factor (ligand) superfamily, member 15 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of TNFSF15 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 4:63,642,837...63,663,296
Ensembl chr 4:63,642,840...63,663,350
|
|
G |
Tnfsf18 |
tumor necrosis factor (ligand) superfamily, member 18 |
multiple interactions |
ISO |
[Aripiprazole co-treated with Ozone] results in increased expression of TNFSF18 mRNA |
CTD |
PMID:31476115 |
|
NCBI chr 1:161,322,221...161,333,903
Ensembl chr 1:161,322,224...161,332,859
|
|
G |
Tubb2a |
tubulin, beta 2A class IIA |
decreases expression |
ISO |
Aripiprazole results in decreased expression of TUBB2A mRNA |
CTD |
PMID:17868501 |
|
NCBI chr13:34,258,261...34,261,991
Ensembl chr13:34,258,257...34,261,990
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Aripiprazole promotes the reaction [Ozone results in increased expression of VEGFA mRNA] |
CTD |
PMID:31476115 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Wee1 |
WEE 1 homolog 1 (S. pombe) |
increases expression |
ISO |
Aripiprazole results in increased expression of WEE1 mRNA |
CTD |
PMID:17868501 |
|
NCBI chr 7:109,721,266...109,742,506
Ensembl chr 7:109,721,253...109,742,493
|
|
G |
Zfp354c |
zinc finger protein 354C |
increases expression |
ISO |
Aripiprazole results in increased expression of ZNF354C mRNA |
CTD |
PMID:17868501 |
|
NCBI chr11:50,701,912...50,718,558
Ensembl chr11:50,701,913...50,718,551
|
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity decreases expression |
ISO |
Asenapine results in decreased activity of CYP1A2 protein Asenapine results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:32941854 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases activity |
ISO |
Azaperone results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases activity |
EXP |
cariprazine results in decreased activity of DHCR7 protein |
CTD |
PMID:29698737 |
|
NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B (MDR/TAP), member 11 |
multiple interactions decreases expression |
ISO EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCB11 mRNA Chlorpromazine results in decreased expression of ABCB11 mRNA; Chlorpromazine results in decreased expression of ABCB11 protein |
CTD |
PMID:27344345 PMID:27765674 PMID:28391356 PMID:35708773 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,960
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
increases expression decreases activity |
ISO |
Chlorpromazine analog results in increased expression of ABCB1 mRNA Chlorpromazine results in decreased activity of ABCB1 protein |
CTD |
PMID:15924885 PMID:16810505 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B (MDR/TAP), member 1B |
affects activity |
ISO |
Chlorpromazine affects the activity of ABCB1B protein |
CTD |
PMID:12626638 |
|
NCBI chr 5:8,848,147...8,916,314
Ensembl chr 5:8,848,147...8,916,315
|
|
G |
Abcb4 |
ATP-binding cassette, sub-family B (MDR/TAP), member 4 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCB4 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231
|
|
G |
Abcb6 |
ATP-binding cassette, sub-family B (MDR/TAP), member 6 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of ABCB6 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:75,148,284...75,157,066
Ensembl chr 1:75,148,361...75,157,036
|
|
G |
Abcb9 |
ATP-binding cassette, sub-family B (MDR/TAP), member 9 |
increases expression |
ISO |
Chlorpromazine results in increased expression of ABCB9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:124,199,920...124,234,009
Ensembl chr 5:124,199,593...124,233,861
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 |
increases expression multiple interactions |
ISO EXP |
Chlorpromazine results in increased expression of ABCC2 mRNA [Bile Acids and Salts co-treated with Chlorpromazine] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:27765674 PMID:35708773 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc3 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 |
increases expression multiple interactions decreases expression |
ISO EXP |
Chlorpromazine analog results in increased expression of ABCC3 mRNA [Bile Acids and Salts co-treated with Chlorpromazine] results in decreased expression of ABCC3 mRNA Chlorpromazine results in decreased expression of ABCC3 mRNA |
CTD |
PMID:15924885 PMID:25596134 PMID:35708773 |
|
NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 |
increases expression |
EXP |
Chlorpromazine results in increased expression of ABCC4 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCG8 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr17:84,983,730...85,007,761
Ensembl chr17:84,983,730...85,007,761
|
|
G |
Acaca |
acetyl-Coenzyme A carboxylase alpha |
decreases phosphorylation |
ISO |
Chlorpromazine results in decreased phosphorylation of ACACA protein |
CTD |
PMID:17512020 |
|
NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477
|
|
G |
Ace2 |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:162,922,338...162,971,414
Ensembl chr X:162,922,328...162,971,416
|
|
G |
Ache |
acetylcholinesterase |
decreases activity increases activity multiple interactions |
ISO EXP |
Chlorpromazine results in decreased activity of ACHE protein Chlorpromazine results in increased activity of ACHE protein Dichlorvos promotes the reaction [Chlorpromazine results in decreased activity of ACHE protein] |
CTD |
PMID:4859365 PMID:29614332 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 9:22,038,023...22,047,042
Ensembl chr 9:22,038,023...22,047,007
|
|
G |
Adra1a |
adrenergic receptor, alpha 1a |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of ADRA1A protein |
CTD |
PMID:23611293 |
|
NCBI chr14:66,872,700...67,008,689
Ensembl chr14:66,872,700...67,008,617
|
|
G |
Adra1b |
adrenergic receptor, alpha 1b |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of ADRA1B protein |
CTD |
PMID:23611293 |
|
NCBI chr11:43,665,432...43,792,076
Ensembl chr11:43,665,433...43,792,037
|
|
G |
Afp |
alpha fetoprotein |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of AFP mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 5:90,638,573...90,656,766
Ensembl chr 5:90,638,596...90,656,766
|
|
G |
Agrn |
agrin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of AGRN mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:156,249,747...156,281,997
Ensembl chr 4:156,249,747...156,281,945
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
affects activity |
ISO |
Chlorpromazine affects the activity of AHR protein |
CTD |
PMID:25596134 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Ak3 |
adenylate kinase 3 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of AK3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:28,968,715...29,026,122
Ensembl chr19:28,998,233...29,025,361
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
decreases phosphorylation |
ISO |
Chlorpromazine results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:17512020 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase family 1, subfamily A1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ALDH1A1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829
|
|
G |
Ap1s1 |
adaptor protein complex AP-1, sigma 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of AP1S1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 5:137,063,847...137,074,962
Ensembl chr 5:137,063,847...137,074,989
|
|
G |
Apoc4 |
apolipoprotein C-IV |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of APOC4 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 7:19,412,009...19,415,385
Ensembl chr 7:19,412,008...19,415,404
|
|
G |
Apof |
apolipoprotein F |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of APOF mRNA |
CTD |
PMID:27344345 |
|
NCBI chr10:128,104,568...128,107,119
Ensembl chr10:128,103,866...128,106,022
|
|
G |
Areg |
amphiregulin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of AREG mRNA |
CTD |
PMID:15924885 PMID:30703373 |
|
NCBI chr 5:91,287,458...91,296,291
Ensembl chr 5:91,287,458...91,296,291
|
|
G |
Arfgef2 |
ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited) |
increases expression |
ISO |
Chlorpromazine results in increased expression of ARFGEF2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:166,647,371...166,739,972
Ensembl chr 2:166,647,508...166,739,972
|
|
G |
Arhgef10 |
Rho guanine nucleotide exchange factor (GEF) 10 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of ARHGEF10 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:14,956,405...15,051,085
Ensembl chr 8:14,961,663...15,051,085
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of ASAH1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 8:41,793,683...41,850,681
Ensembl chr 8:41,793,234...41,827,810
|
|
G |
Asns |
asparagine synthetase |
increases expression |
ISO |
Chlorpromazine results in increased expression of ASNS mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 6:7,675,169...7,693,209
Ensembl chr 6:7,675,169...7,693,254
|
|
G |
Atf4 |
activating transcription factor 4 |
affects activity multiple interactions |
ISO |
Chlorpromazine affects the activity of ATF4 protein [Chlorpromazine co-treated with Cholic Acids] affects the expression of ATF4 mRNA |
CTD |
PMID:25596134 PMID:27344345 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atp6v1b2 |
ATPase, H+ transporting, lysosomal V1 subunit B2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of ATP6V1B2 protein |
CTD |
PMID:19441803 |
|
NCBI chr 8:69,541,388...69,566,370
Ensembl chr 8:69,541,298...69,566,363
|
|
G |
Avp |
arginine vasopressin |
increases expression multiple interactions |
ISO |
Chlorpromazine results in increased expression of AVP protein Chlorpromazine inhibits the reaction [Lithium results in increased expression of AVP protein] |
CTD |
PMID:3567260 PMID:3976404 |
|
NCBI chr 2:130,422,540...130,424,508
Ensembl chr 2:130,422,540...130,424,474
|
|
G |
Bag4 |
BCL2-associated athanogene 4 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of BAG4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 8:26,254,566...26,275,237
Ensembl chr 8:26,254,566...26,275,315
|
|
G |
Bcl2l1 |
BCL2-like 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of BCL2L1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bdnf |
brain derived neurotrophic factor |
affects response to substance affects expression |
ISO |
BDNF affects the susceptibility to Chlorpromazine Chlorpromazine affects the expression of BDNF mRNA |
CTD |
PMID:18408624 PMID:31324950 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of BHLHE40 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 6:108,637,590...108,643,886
Ensembl chr 6:108,637,590...108,643,886
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of BIRC2 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 9:7,818,227...7,837,123
Ensembl chr 9:7,818,228...7,837,065
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of BIRC5 mRNA; Chlorpromazine results in decreased expression of BIRC5 mRNA |
CTD |
PMID:15924885 PMID:30703373 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Bnip3 |
BCL2/adenovirus E1B interacting protein 3 |
increases expression |
ISO |
Chlorpromazine results in increased expression of BNIP3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of BTG2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:134,002,603...134,006,893
Ensembl chr 1:134,002,908...134,006,858
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of BTG3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr16:78,156,748...78,174,069
Ensembl chr16:78,129,525...78,174,080
|
|
G |
C3 |
complement component 3 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of C3 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136
|
|
G |
C6 |
complement component 6 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of C6 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr15:4,756,550...4,833,527
Ensembl chr15:4,756,657...4,844,449
|
|
G |
Calcr |
calcitonin receptor |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 6:3,685,678...3,764,713
Ensembl chr 6:3,685,680...3,764,714
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CALR mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CAR2 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830
|
|
G |
Cat |
catalase |
multiple interactions decreases expression decreases activity |
ISO |
carvedilol inhibits the reaction [Chlorpromazine results in decreased expression of CAT protein]; zolpidem inhibits the reaction [Chlorpromazine results in decreased activity of CAT] |
CTD |
PMID:12010767 PMID:17513028 PMID:25449126 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CCN2 mRNA; Chlorpromazine results in decreased expression of CCN2 protein |
CTD |
PMID:30703373 |
|
NCBI chr10:24,471,340...24,474,581
Ensembl chr10:24,471,340...24,474,581
|
|
G |
Ccn3 |
cellular communication network factor 3 |
affects expression |
ISO |
Chlorpromazine affects the expression of CCN3 mRNA |
CTD |
PMID:31324950 |
|
NCBI chr15:54,609,306...54,617,158
Ensembl chr15:54,609,098...54,617,435
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CCNB2 mRNA; Chlorpromazine results in decreased expression of CCNB2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 9:70,314,971...70,328,836
Ensembl chr 9:70,314,974...70,328,829
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CCND1 mRNA |
CTD |
PMID:17202759 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CCND3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr17:47,815,976...47,910,614
Ensembl chr17:47,815,976...47,910,616
|
|
G |
Ccnf |
cyclin F |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CCNF mRNA |
CTD |
PMID:15924885 |
|
NCBI chr17:24,441,518...24,470,333
Ensembl chr17:24,441,172...24,470,458
|
|
G |
Cd274 |
CD274 antigen |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [platycodin D results in decreased expression of and results in increased secretion of CD274 protein] |
CTD |
PMID:31150782 |
|
NCBI chr19:29,339,428...29,365,495
Ensembl chr19:29,344,855...29,365,495
|
|
G |
Cd44 |
CD44 antigen |
multiple interactions decreases expression |
EXP ISO |
Chlorpromazine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD44 protein] Chlorpromazine results in decreased expression of CD44 protein |
CTD |
PMID:9929743 PMID:30703373 |
|
NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010
|
|
G |
Cd86 |
CD86 antigen |
increases expression |
ISO |
Chlorpromazine results in increased expression of CD86 protein |
CTD |
PMID:19665512 |
|
NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443
|
|
G |
Cdk5 |
cyclin dependent kinase 5 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CDK5 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 5:24,612,595...24,628,737
Ensembl chr 5:24,623,239...24,628,528
|
|
G |
Cdk7 |
cyclin dependent kinase 7 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of CDK7 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr13:100,833,532...100,867,454
Ensembl chr13:100,839,139...100,867,447
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A (P21) |
multiple interactions increases expression |
ISO |
[EGR1 binds to CDKN1A promoter] promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; EGR1 promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA] |
CTD |
PMID:20368687 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn2c |
cyclin dependent kinase inhibitor 2C |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CDKN2C mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 4:109,518,073...109,523,953
Ensembl chr 4:109,518,073...109,524,386
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CES2 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 8:105,727,462...105,747,042
Ensembl chr 8:105,727,485...105,747,810
|
|
G |
Cfh |
complement component factor h |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CFH mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 1:140,013,593...140,111,149
Ensembl chr 1:140,012,446...140,111,502
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CGREF1 mRNA |
CTD |
PMID:17202759 |
|
NCBI chr 5:31,090,487...31,102,771
Ensembl chr 5:31,090,487...31,102,935
|
|
G |
Chtf18 |
CTF18, chromosome transmission fidelity factor 18 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CHTF18 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr17:25,938,004...25,946,409
Ensembl chr17:25,937,900...25,946,393
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CITED2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr10:17,598,452...17,601,422
Ensembl chr10:17,598,966...17,601,422
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CKS2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr13:51,799,268...51,804,698
Ensembl chr13:51,799,268...51,804,696
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of CLCF1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr19:4,264,479...4,273,548
Ensembl chr19:4,264,292...4,273,544
|
|
G |
Col18a1 |
collagen, type XVIII, alpha 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of COL18A1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr10:76,888,013...77,002,351
Ensembl chr10:76,888,012...77,002,382
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of COL1A1 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Col4a1 |
collagen, type IV, alpha 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of COL4A1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:11,248,423...11,362,889
Ensembl chr 8:11,248,423...11,362,826
|
|
G |
Cort |
cortistatin |
affects expression |
ISO |
Chlorpromazine affects the expression of CORT mRNA |
CTD |
PMID:31324950 |
|
NCBI chr 4:149,209,491...149,211,220
Ensembl chr 4:149,209,491...149,211,220
|
|
G |
Cox8a |
cytochrome c oxidase subunit 8A |
affects expression increases expression |
ISO |
Chlorpromazine affects the expression of COX8A mRNA Chlorpromazine results in increased expression of COX8A mRNA |
CTD |
PMID:18246545 |
|
NCBI chr19:7,192,523...7,194,981
Ensembl chr19:7,192,518...7,194,981
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560
|
|
G |
Cth |
cystathionase (cystathionine gamma-lyase) |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CTH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 3:95,406,521...95,416,698
Ensembl chr 3:95,406,567...95,416,673
|
|
G |
Cxcl15 |
chemokine (C-X-C motif) ligand 15 |
increases expression multiple interactions |
ISO |
Chlorpromazine results in increased expression of CXCL8 mRNA [Chlorpromazine co-treated with lipopolysaccharide, E. coli O26-B6] results in decreased expression of CXCL8 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity decreases response to substance increases expression |
ISO |
[Filipin co-treated with Chlorpromazine co-treated with Wortmannin] inhibits the reaction [Particulate Matter results in increased expression of CYP1A1 mRNA]; Chlorpromazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Chlorpromazine results in decreased activity of CYP1A1 protein CYP1A1 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:17202759 PMID:18246545 PMID:18493746 PMID:25596134 PMID:26477383 PMID:29724254 PMID:33814510 More...
|
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases response to substance increases expression increases oxidation affects expression decreases methylation |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CYP1A2 mRNA; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine; Chlorpromazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]; CYP1A2 protein results in increased metabolism of and results in increased activity of Chlorpromazine CYP1A2 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in increased expression of CYP1A2 mRNA CYP1A2 protein results in increased oxidation of Chlorpromazine Chlorpromazine affects the expression of CYP1A2 mRNA CYP1A2 protein results in decreased methylation of Chlorpromazine |
CTD |
PMID:18246545 PMID:18493746 PMID:19482014 PMID:20615392 PMID:23397584 PMID:25596134 PMID:26477383 PMID:27344345 More...
|
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases response to substance decreases activity multiple interactions |
ISO |
CYP1B1 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of CYP1B1 protein [Filipin co-treated with Chlorpromazine co-treated with Wortmannin] inhibits the reaction [Particulate Matter results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:26477383 PMID:29724254 PMID:33814510 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp2a5 |
cytochrome P450, family 2, subfamily a, polypeptide 5 |
decreases activity decreases response to substance |
ISO |
Chlorpromazine results in decreased activity of CYP2A6 protein CYP2A6 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:15135088 PMID:26477383 |
|
NCBI chr 7:26,534,764...26,542,689
Ensembl chr 7:26,534,730...26,542,973
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
multiple interactions decreases response to substance |
EXP ISO |
NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP2B10 mRNA] CYP2B6 protein results in decreased susceptibility to Chlorpromazine [Chlorpromazine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; Chlorpromazine inhibits the reaction [Androstenols inhibits the reaction [NR1I3 protein results in increased expression of CYP2B6 mRNA]] |
CTD |
PMID:10037683 PMID:12049174 PMID:17041008 PMID:26477383 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp2c29 |
cytochrome P450, family 2, subfamily c, polypeptide 29 |
decreases response to substance |
ISO |
CYP2C8 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:26477383 |
|
NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157
|
|
G |
Cyp2c38 |
cytochrome P450, family 2, subfamily c, polypeptide 38 |
decreases activity decreases response to substance affects methylation multiple interactions |
ISO |
Chlorpromazine results in decreased activity of CYP2C19 protein CYP2C19 protein results in decreased susceptibility to Chlorpromazine CYP2C19 protein affects the methylation of Chlorpromazine [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine |
CTD |
PMID:15135088 PMID:20615392 PMID:23397584 PMID:26477383 |
|
NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519
|
|
G |
Cyp2c52-ps |
cytochrome P450, family 2, subfamily c, polypeptide 52, pseudogene |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CYP2C mRNA; Chlorpromazine results in decreased expression of CYP2C11 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr19:38,965,106...38,992,071
Ensembl chr19:38,965,091...38,991,733
|
|
G |
Cyp2c55 |
cytochrome P450, family 2, subfamily c, polypeptide 55 |
decreases response to substance |
ISO |
CYP2C18 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:26477383 |
|
NCBI chr19:38,995,384...39,031,134
Ensembl chr19:38,995,463...39,031,137
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
decreases activity multiple interactions decreases response to substance |
ISO |
Chlorpromazine results in decreased activity of CYP2C9 protein [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine CYP2C9 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:15135088 PMID:23397584 PMID:26477383 |
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
G |
Cyp2c66 |
cytochrome P450, family 2, subfamily c, polypeptide 66 |
decreases activity multiple interactions decreases response to substance |
ISO |
Chlorpromazine results in decreased activity of CYP2C9 protein [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine CYP2C9 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:15135088 PMID:23397584 PMID:26477383 |
|
NCBI chr19:39,102,342...39,175,200
Ensembl chr19:39,102,342...39,175,516
|
|
G |
Cyp2d22 |
cytochrome P450, family 2, subfamily d, polypeptide 22 |
multiple interactions decreases response to substance |
ISO |
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine; CYP2D6 protein results in increased metabolism of and results in increased activity of Chlorpromazine CYP2D6 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:19482014 PMID:23397584 PMID:26477383 |
|
NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity decreases response to substance |
ISO |
Chlorpromazine results in decreased activity of CYP2E1 protein CYP2E1 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:15135088 PMID:26477383 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Cyp3a11 |
cytochrome P450, family 3, subfamily a, polypeptide 11 |
multiple interactions decreases response to substance |
EXP ISO |
NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP3A11 mRNA] CYP3A5 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:12049174 PMID:26477383 |
|
NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774
|
|
G |
Cyp3a13 |
cytochrome P450, family 3, subfamily a, polypeptide 13 |
decreases response to substance |
ISO |
CYP3A7 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:26477383 |
|
NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881
|
|
G |
Cyp8b1 |
cytochrome P450, family 8, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CYP8B1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 9:121,743,422...121,745,371
Ensembl chr 9:121,743,422...121,745,371
|
|
G |
Dao |
D-amino acid oxidase |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of DAO protein |
CTD |
PMID:18615285 |
|
NCBI chr 5:114,137,696...114,163,736
Ensembl chr 5:114,141,764...114,163,743
|
|
G |
Dcstamp |
dendrocyte expressed seven transmembrane protein |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr15:39,609,326...39,624,334
Ensembl chr15:39,609,326...39,624,334
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Chlorpromazine results in increased expression of DDIT3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Depp1 |
DEPP1 autophagy regulator |
increases expression |
ISO |
Chlorpromazine results in increased expression of DEPP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 6:116,627,645...116,629,808
Ensembl chr 6:116,627,570...116,629,755
|
|
G |
Drd1 |
dopamine receptor D1 |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of DRD1 protein |
CTD |
PMID:23611293 |
|
NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases response to substance decreases activity |
ISO |
DRD2 polymorphism results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of DRD2 protein |
CTD |
PMID:15694263 PMID:23611293 |
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression affects expression |
ISO EXP |
Chlorpromazine analog results in increased expression of DUSP1 mRNA Chlorpromazine affects the expression of DUSP1 mRNA |
CTD |
PMID:15924885 PMID:20843724 |
|
NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102
|
|
G |
Dusp9 |
dual specificity phosphatase 9 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of DUSP9 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:72,682,995...72,687,120
Ensembl chr X:72,683,025...72,687,120
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of E2F1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
ISO |
Chlorpromazine results in increased expression of EGR1 [EGR1 binds to CDKN1A promoter] promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; EGR1 promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; MAPK1 affects the reaction [Chlorpromazine results in increased expression of EGR1]; MAPK3 affects the reaction [Chlorpromazine results in increased expression of EGR1] |
CTD |
PMID:20368687 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Eif1 |
eukaryotic translation initiation factor 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of EIF1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:100,210,775...100,212,925
Ensembl chr11:100,210,711...100,212,922
|
|
G |
Eno2 |
enolase 2, gamma neuronal |
increases expression |
ISO |
Chlorpromazine results in increased expression of ENO2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:124,737,018...124,746,489
Ensembl chr 6:124,737,016...124,746,636
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
increases expression |
ISO |
Chlorpromazine results in increased expression of ERO1A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr14:45,520,544...45,556,029
Ensembl chr14:45,520,544...45,556,228
|
|
G |
F2 |
coagulation factor II |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of F2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 2:91,442,742...91,466,799
Ensembl chr 2:91,455,665...91,466,759
|
|
G |
Fabp1 |
fatty acid binding protein 1, liver |
increases expression |
ISO |
Chlorpromazine results in increased expression of FABP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 6:71,176,863...71,182,018
Ensembl chr 6:71,176,811...71,182,007
|
|
G |
Fas |
Fas (TNF receptor superfamily member 6) |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of FAS mRNA |
CTD |
PMID:15924885 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fbp1 |
fructose bisphosphatase 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FBP1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr13:63,012,567...63,036,112
Ensembl chr13:63,012,567...63,036,096
|
|
G |
Fbxo22 |
F-box protein 22 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of FBXO22 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:55,116,219...55,131,717
Ensembl chr 9:55,116,209...55,131,717
|
|
G |
Fech |
ferrochelatase |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of FECH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:64,589,613...64,622,169
Ensembl chr18:64,585,985...64,623,322
|
|
G |
Fetub |
fetuin beta |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FETUB mRNA |
CTD |
PMID:27344345 |
|
NCBI chr16:22,737,132...22,758,518
Ensembl chr16:22,737,084...22,758,528
|
|
G |
Fga |
fibrinogen alpha chain |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FGA mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 3:82,933,460...82,940,934
Ensembl chr 3:82,933,383...82,940,934
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FGF2 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257
|
|
G |
Fgfr1 |
fibroblast growth factor receptor 1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of FGFR1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 8:26,008,808...26,067,819
Ensembl chr 8:26,003,670...26,065,734
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of FGR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:132,701,406...132,729,204
Ensembl chr 4:132,701,406...132,729,221
|
|
G |
Fkbp5 |
FK506 binding protein 5 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Lipopolysaccharides results in decreased expression of FKBP5 protein] |
CTD |
PMID:21034739 |
|
NCBI chr17:28,617,727...28,705,123
Ensembl chr17:28,618,068...28,736,501
|
|
G |
Fndc4 |
fibronectin type III domain containing 4 |
increases expression |
ISO |
Chlorpromazine results in increased expression of FNDC4 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 5:31,449,586...31,453,279
Ensembl chr 5:31,449,586...31,453,424
|
|
G |
Fos |
FBJ osteosarcoma oncogene |
affects expression |
EXP |
Chlorpromazine affects the expression of FOS mRNA |
CTD |
PMID:20843724 |
|
NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047
|
|
G |
Fosb |
FBJ osteosarcoma oncogene B |
affects expression |
EXP |
Chlorpromazine affects the expression of FOSB mRNA |
CTD |
PMID:20843724 |
|
NCBI chr 7:19,036,621...19,043,970
Ensembl chr 7:19,036,621...19,043,976
|
|
G |
Fosl1 |
fos-like antigen 1 |
increases expression affects expression |
ISO EXP |
Chlorpromazine analog results in increased expression of FOSL1 mRNA Chlorpromazine affects the expression of FOSL1 mRNA |
CTD |
PMID:15924885 PMID:20843724 |
|
NCBI chr19:5,497,726...5,505,966
Ensembl chr19:5,497,575...5,505,974
|
|
G |
Fosl2 |
fos-like antigen 2 |
affects expression |
EXP |
Chlorpromazine affects the expression of FOSL2 mRNA |
CTD |
PMID:20843724 |
|
NCBI chr 5:32,292,599...32,315,184
Ensembl chr 5:32,293,145...32,315,186
|
|
G |
Fth1 |
ferritin heavy polypeptide 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FTH1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr19:9,957,964...9,962,475
Ensembl chr19:9,957,962...9,962,462
|
|
G |
G6pdx |
glucose-6-phosphate dehydrogenase X-linked |
decreases expression multiple interactions decreases activity |
ISO |
Chlorpromazine analog results in decreased expression of G6PD mRNA [Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein]; coenzyme Q10 inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein]; Taurine inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein] |
CTD |
PMID:15924885 PMID:33548410 |
|
NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
decreases methylation multiple interactions |
EXP |
Chlorpromazine results in decreased methylation of GAD1 promoter Valproic Acid promotes the reaction [Chlorpromazine results in decreased methylation of GAD1 promoter] |
CTD |
PMID:19110320 |
|
NCBI chr 2:70,391,644...70,432,358
Ensembl chr 2:70,383,416...70,432,358
|
|
G |
Gcgr |
glucagon receptor |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of GCGR mRNA |
CTD |
PMID:27344345 |
|
NCBI chr11:120,420,011...120,429,815
Ensembl chr11:120,421,525...120,429,812
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of GCLC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
Chlorpromazine results in increased expression of GDF15 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106
|
|
G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
increases expression |
ISO |
Chlorpromazine results in increased expression of GDPD3 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 7:126,365,586...126,374,817
Ensembl chr 7:126,365,506...126,374,821
|
|
G |
Gfap |
glial fibrillary acidic protein |
affects expression |
ISO |
Chlorpromazine affects the expression of GFAP mRNA |
CTD |
PMID:31324950 |
|
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
|
|
G |
Gpnmb |
glycoprotein (transmembrane) nmb |
increases expression |
ISO |
Chlorpromazine results in increased expression of GPNMB mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:49,013,449...49,044,413
Ensembl chr 6:49,013,480...49,047,863
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
increases expression |
ISO |
Chlorpromazine results in increased expression of GPT protein |
CTD |
PMID:35722787 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gsr |
glutathione reductase |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of GSR protein |
CTD |
PMID:6693892 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
affects activity |
ISO |
Chlorpromazine affects the activity of HIF1A protein |
CTD |
PMID:25596134 |
|
NCBI chr12:73,948,098...73,994,328
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
increases expression |
ISO |
Chlorpromazine results in increased expression of HMGCR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr13:96,785,470...96,807,444
Ensembl chr13:96,785,475...96,807,444
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17052361 |
|
NCBI chr13:120,151,887...120,169,796
Ensembl chr13:120,151,915...120,169,796
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression affects expression |
ISO |
Chlorpromazine results in increased expression of HMOX1 mRNA Chlorpromazine affects the expression of HMOX1 mRNA |
CTD |
PMID:15924885 PMID:25596134 PMID:31324950 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hpn |
hepsin |
increases expression |
ISO |
Chlorpromazine results in increased expression of HPN mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 7:30,798,150...30,814,751
Ensembl chr 7:30,798,150...30,814,715
|
|
G |
Ibsp |
integrin binding sialoprotein |
decreases expression multiple interactions |
ISO |
Chlorpromazine results in decreased expression of IBSP mRNA herbimycin inhibits the reaction [Chlorpromazine results in decreased expression of IBSP mRNA]; U 0126 inhibits the reaction [Chlorpromazine results in decreased expression of IBSP mRNA] |
CTD |
PMID:16294319 |
|
NCBI chr 5:104,447,153...104,459,338
Ensembl chr 5:104,447,037...104,459,335
|
|
G |
Ifnb1 |
interferon beta 1, fibroblast |
multiple interactions |
ISO |
Chlorpromazine promotes the reaction [PAM2-CSK4 results in increased expression of IFNB1 mRNA] |
CTD |
PMID:32796029 |
|
NCBI chr 4:88,440,253...88,441,083
Ensembl chr 4:88,440,262...88,441,011
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Ifnlr1 |
interferon lambda receptor 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of IFNLR1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 4:135,413,513...135,435,492
Ensembl chr 4:135,413,598...135,435,492
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546
|
|
G |
Ikbkg |
inhibitor of kappaB kinase gamma |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of IKBKG mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:73,436,883...73,498,013
Ensembl chr X:73,436,896...73,497,460
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine |
CTD |
PMID:19362101 |
|
NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11014349 PMID:29594315 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine |
CTD |
PMID:19362101 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Inhbe |
inhibin beta-E |
increases expression |
ISO |
Chlorpromazine results in increased expression of INHBE mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr10:127,185,271...127,187,717
Ensembl chr10:127,184,726...127,190,280
|
|
G |
Ins1 |
insulin I |
decreases secretion |
ISO |
Chlorpromazine results in decreased secretion of INS1 protein |
CTD |
PMID:18308779 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Insig2 |
insulin induced gene 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of INSIG2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:121,232,082...121,260,391
Ensembl chr 1:121,232,082...121,260,318
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
Chlorpromazine results in decreased expression of and results in decreased phosphorylation of IRS2 protein; Chlorpromazine results in decreased expression of and results in increased degradation of IRS2 protein |
CTD |
PMID:17512020 PMID:18308779 |
|
NCBI chr 8:11,034,681...11,058,929
Ensembl chr 8:11,034,681...11,058,458
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
multiple interactions decreases activity |
ISO |
Chlorpromazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Chlorpromazine results in decreased activity of KCNH2 protein |
CTD |
PMID:15071359 PMID:21158687 PMID:24052561 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Kcnn2 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of KCNN2 protein |
CTD |
PMID:10915830 |
|
NCBI chr18:45,401,754...45,818,954
Ensembl chr18:45,401,927...45,819,091
|
|
G |
Klf4 |
Kruppel-like transcription factor 4 (gut) |
multiple interactions decreases expression |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KLF4 mRNA Chlorpromazine results in decreased expression of KLF4 mRNA |
CTD |
PMID:27344345 PMID:30703373 |
|
NCBI chr 4:55,527,137...55,536,984
Ensembl chr 4:55,527,143...55,532,466
|
|
G |
Klkb1 |
kallikrein B, plasma 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KLKB1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 8:45,719,725...45,747,872
Ensembl chr 8:45,719,726...45,747,896
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KNG1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr16:22,804,602...22,847,851
Ensembl chr16:22,804,604...22,848,232
|
|
G |
Lats1 |
large tumor suppressor |
increases phosphorylation |
ISO |
Chlorpromazine results in increased phosphorylation of LATS1 protein |
CTD |
PMID:30703373 |
|
NCBI chr10:7,556,964...7,592,225
Ensembl chr10:7,556,978...7,592,224
|
|
G |
Ldhc |
lactate dehydrogenase C |
multiple interactions decreases activity |
ISO |
[Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein]; coenzyme Q10 inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein]; Taurine inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein] |
CTD |
PMID:33548410 |
|
NCBI chr 7:46,510,687...46,527,571
Ensembl chr 7:46,510,627...46,527,566
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Chlorpromazine results in increased expression of LDLR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Lep |
leptin |
increases expression |
ISO |
Chlorpromazine results in increased expression of LEP protein |
CTD |
PMID:17512020 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lss |
lanosterol synthase |
increases expression |
ISO |
Chlorpromazine results in increased expression of LSS mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr10:76,367,303...76,392,973
Ensembl chr10:76,367,422...76,392,972
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of MAP2 mRNA |
CTD |
PMID:15079866 |
|
NCBI chr 1:66,214,337...66,481,742
Ensembl chr 1:66,214,432...66,481,742
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein] MAPK1 affects the reaction [Chlorpromazine results in increased expression of EGR1] |
CTD |
PMID:11014349 PMID:20368687 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk14 |
mitogen-activated protein kinase 14 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MAPK14 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr17:28,910,243...28,967,379
Ensembl chr17:28,910,303...28,967,380
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
decreases expression multiple interactions |
ISO |
Chlorpromazine analog results in decreased expression of MAPK3 mRNA MAPK3 affects the reaction [Chlorpromazine results in increased expression of EGR1] Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11014349 PMID:15924885 PMID:20368687 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein; Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]] |
CTD |
PMID:23238562 |
|
NCBI chr14:33,099,855...33,169,215
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapkapk2 |
MAP kinase-activated protein kinase 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of MAPKAPK2 mRNA |
CTD |
PMID:19441803 |
|
NCBI chr 1:130,981,437...131,025,580
Ensembl chr 1:130,981,437...131,025,563
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MCM3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:20,873,188...20,890,536
Ensembl chr 1:20,873,192...20,890,536
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MCM5 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 8:75,836,096...75,855,067
Ensembl chr 8:75,836,197...75,855,067
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of MDM2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Mitf |
melanogenesis associated transcription factor |
increases expression |
ISO |
Chlorpromazine results in increased expression of MITF protein |
CTD |
PMID:25449126 |
|
NCBI chr 6:97,783,966...97,998,321
Ensembl chr 6:97,784,013...97,998,310
|
|
G |
Mki67 |
antigen identified by monoclonal antibody Ki 67 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MKI67 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased expression of MMP9 mRNA]; Chlorpromazine inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased secretion of MMP9 protein] |
CTD |
PMID:25200491 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Msc |
musculin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of MSC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:14,823,570...14,826,216
Ensembl chr 1:14,823,570...14,826,216
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of MSH2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr17:87,979,960...88,031,141
Ensembl chr17:87,979,758...88,031,141
|
|
G |
Mst1 |
macrophage stimulating 1 (hepatocyte growth factor-like) |
increases phosphorylation |
ISO |
Chlorpromazine results in increased phosphorylation of MST1 protein |
CTD |
PMID:30703373 |
|
NCBI chr 9:107,957,607...107,962,226
Ensembl chr 9:107,957,635...107,962,202
|
|
G |
Mybl2 |
myeloblastosis oncogene-like 2 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MYBL2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 2:162,896,246...162,926,608
Ensembl chr 2:162,896,607...162,926,608
|
|
G |
Myc |
myelocytomatosis oncogene |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of MYC mRNA |
CTD |
PMID:30703373 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
increases expression |
ISO |
Chlorpromazine results in increased expression of NAMPT mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:32,870,334...32,903,368
Ensembl chr12:32,869,544...32,903,348
|
|
G |
Nanog |
Nanog homeobox |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of NANOG mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 6:122,684,448...122,691,592
Ensembl chr 6:122,684,448...122,691,592
|
|
G |
Ndufs3 |
NADH:ubiquinone oxidoreductase core subunit S3 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of NDUFS3 protein |
CTD |
PMID:19441803 |
|
NCBI chr 2:90,724,971...90,735,065
Ensembl chr 2:90,724,978...90,735,171
|
|
G |
Nectin2 |
nectin cell adhesion molecule 2 |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [Cadmium Chloride results in decreased expression of and affects the localization of NECTIN2 protein] |
CTD |
PMID:25046863 |
|
NCBI chr 7:19,450,569...19,483,498
Ensembl chr 7:19,450,569...19,484,408
|
|
G |
Nedd9 |
neural precursor cell expressed, developmentally down-regulated gene 9 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of NEDD9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:41,463,392...41,640,836
Ensembl chr13:41,463,057...41,640,838
|
|
G |
Nefh |
neurofilament, heavy polypeptide |
affects expression |
ISO |
Chlorpromazine affects the expression of NEFH mRNA |
CTD |
PMID:31324950 |
|
NCBI chr11:4,888,754...4,898,064
Ensembl chr11:4,888,754...4,898,064
|
|
G |
Nfatc1 |
nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1 |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr18:80,649,418...80,756,286
Ensembl chr18:80,649,420...80,756,286
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
decreases expression affects activity |
ISO |
Chlorpromazine results in decreased expression of NFE2L2 mRNA Chlorpromazine affects the activity of NFE2L2 protein |
CTD |
PMID:25596134 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Ninj1 |
ninjurin 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of NINJ1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:49,341,005...49,349,727
Ensembl chr13:49,340,961...49,349,720
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of NR0B2 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of NR1H4 mRNA |
CTD |
PMID:27765674 PMID:28391356 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression multiple interactions |
ISO |
Chlorpromazine analog results in increased expression of NR1I2 mRNA [Chlorpromazine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:15924885 PMID:17041008 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity increases expression multiple interactions |
EXP ISO |
Chlorpromazine results in increased activity of NR1I3 protein Chlorpromazine results in increased expression of NR1I3 mRNA [Chlorpromazine co-treated with Cholic Acids] affects the expression of NR1I3 mRNA; [Chlorpromazine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; Chlorpromazine inhibits the reaction [Androstenols inhibits the reaction [NR1I3 protein results in increased expression of CYP2B6 mRNA]] NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP2B10 mRNA]; NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP3A11 mRNA] |
CTD |
PMID:10037683 PMID:12049174 PMID:12948398 PMID:17041008 PMID:22310298 PMID:27344345 More...
|
|
NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein] |
CTD |
PMID:16581232 |
|
NCBI chr18:39,543,598...39,652,485
Ensembl chr18:39,543,598...39,652,474
|
|
G |
Nupr1 |
nuclear protein transcription regulator 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of NUPR1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 7:126,222,418...126,224,642
Ensembl chr 7:126,222,421...126,230,033
|
|
G |
Orc1 |
origin recognition complex, subunit 1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of ORC1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 4:108,436,651...108,472,030
Ensembl chr 4:108,436,620...108,472,030
|
|
G |
Orm1 |
orosomucoid 1 |
affects binding multiple interactions |
ISO |
Chlorpromazine binds to ORM1 protein alternative form Chlorpromazine inhibits the reaction [Warfarin binds to ORM1 protein alternative form] |
CTD |
PMID:8946472 |
|
NCBI chr 4:63,262,793...63,266,400
Ensembl chr 4:63,262,797...63,266,400
|
|
G |
Orm2 |
orosomucoid 2 |
affects binding multiple interactions |
ISO |
Chlorpromazine binds to ORM2 protein alternative form Chlorpromazine inhibits the reaction [Imipramine binds to ORM2 protein alternative form] |
CTD |
PMID:8946472 |
|
NCBI chr 4:63,280,543...63,284,114
Ensembl chr 4:63,280,686...63,284,115
|
|
G |
Pdia2 |
protein disulfide isomerase associated 2 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of PDIA2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr17:26,414,973...26,418,108
Ensembl chr17:26,414,973...26,418,061
|
|
G |
Pdia5 |
protein disulfide isomerase associated 5 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of PDIA5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:35,217,678...35,311,289
Ensembl chr16:35,217,682...35,311,243
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase, isoenzyme 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of PDK1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:71,703,398...71,734,202
Ensembl chr 2:71,703,568...71,734,202
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase, isoenzyme 4 |
increases expression |
ISO |
Chlorpromazine results in increased expression of PDK4 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309
|
|
G |
Phyh |
phytanoyl-CoA hydroxylase |
increases expression |
ISO |
Chlorpromazine results in increased expression of PHYH mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 2:4,923,807...4,943,554
Ensembl chr 2:4,923,830...4,943,541
|
|
G |
Pias1 |
protein inhibitor of activated STAT 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of PIAS1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 9:62,785,648...62,888,161
Ensembl chr 9:62,785,650...62,895,206
|
|
G |
Pim1 |
proviral integration site 1 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of PIM1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr17:29,709,759...29,715,085
Ensembl chr17:29,709,727...29,715,086
|
|
G |
Pir |
pirin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of PIR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr X:163,052,427...163,156,009
Ensembl chr X:163,052,367...163,156,007
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of PLIN2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:86,545,147...86,588,518
Ensembl chr 4:86,566,623...86,588,297
|
|
G |
Pmepa1 |
prostate transmembrane protein, androgen induced 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of PMEPA1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:173,066,251...173,118,329
Ensembl chr 2:173,066,251...173,118,326
|
|
G |
Pola1 |
polymerase (DNA directed), alpha 1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of POLA1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:92,348,372...92,675,993
Ensembl chr X:92,348,373...92,675,761
|
|
G |
Pold4 |
polymerase (DNA-directed), delta 4 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of POLD4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr19:4,281,947...4,283,688
Ensembl chr19:4,281,953...4,283,688
|
|
G |
Pou5f1 |
POU domain, class 5, transcription factor 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of POU5F1 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr17:35,816,929...35,821,674
Ensembl chr17:35,816,915...35,821,669
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
affects activity |
ISO |
Chlorpromazine affects the activity of PPARG protein |
CTD |
PMID:25596134 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
ISO |
Chlorpromazine results in increased expression of PPP1R15A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:45,172,341...45,175,692
Ensembl chr 7:45,172,340...45,175,692
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
decreases phosphorylation |
ISO |
Chlorpromazine results in decreased phosphorylation of PRKAA1 protein |
CTD |
PMID:17512020 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Chlorpromazine results in increased expression of PRL protein |
CTD |
PMID:718334 PMID:996201 |
|
NCBI chr13:27,241,553...27,249,187
Ensembl chr13:27,241,553...27,249,188
|
|
G |
Rara |
retinoic acid receptor, alpha |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of RARA mRNA |
CTD |
PMID:18246545 |
|
NCBI chr11:98,818,626...98,865,768
Ensembl chr11:98,818,644...98,865,768
|
|
G |
Rnd1 |
Rho family GTPase 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of RND1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr15:98,567,086...98,575,342
Ensembl chr15:98,561,302...98,575,342
|
|
G |
Rnd3 |
Rho family GTPase 3 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of RND3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:51,020,451...51,039,123
Ensembl chr 2:51,020,450...51,039,123
|
|
G |
Rnf121 |
ring finger protein 121 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of RNF121 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:101,668,344...101,721,712
Ensembl chr 7:101,668,344...101,714,676
|
|
G |
Runx1 |
runt related transcription factor 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of RUNX1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:92,398,354...92,622,962
Ensembl chr16:92,398,354...92,623,037
|
|
G |
Rxrg |
retinoid X receptor gamma |
affects response to substance |
EXP |
RXRG protein affects the susceptibility to Chlorpromazine |
CTD |
PMID:10336693 |
|
NCBI chr 1:167,425,931...167,467,192
Ensembl chr 1:167,425,953...167,467,192
|
|
G |
Sat1 |
spermidine/spermine N1-acetyl transferase 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SAT1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr X:153,996,122...153,999,445
Ensembl chr X:153,996,128...153,999,445
|
|
G |
Sc5d |
sterol-C5-desaturase |
increases expression |
ISO |
Chlorpromazine results in increased expression of SC5D mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 9:42,162,888...42,175,607
Ensembl chr 9:42,162,891...42,175,552
|
|
G |
Serpina3b |
serine (or cysteine) peptidase inhibitor, clade A, member 3B |
increases expression |
ISO |
Chlorpromazine results in increased expression of SERPINA3 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr12:104,094,245...104,105,805
Ensembl chr12:104,094,255...104,105,804
|
|
G |
Serpinh1 |
serine (or cysteine) peptidase inhibitor, clade H, member 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SERPINH1 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr 7:98,994,583...99,002,321
Ensembl chr 7:98,994,583...99,002,446
|
|
G |
Sesn1 |
sestrin 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SESN1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:41,686,570...41,784,432
Ensembl chr10:41,685,931...41,784,420
|
|
G |
Sik1 |
salt inducible kinase 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SIK1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:32,063,222...32,074,808
Ensembl chr17:32,063,224...32,074,778
|
|
G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
decreases expression increases expression |
ISO EXP |
Chlorpromazine results in decreased expression of SLC10A1 mRNA Chlorpromazine results in increased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 PMID:28391356 PMID:35708773 |
|
NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479
|
|
G |
Slc12a8 |
solute carrier family 12 (potassium/chloride transporters), member 8 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SLC12A8 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:33,337,440...33,484,508
Ensembl chr16:33,337,698...33,484,505
|
|
G |
Slc19a1 |
solute carrier family 19 (folate transporter), member 1 |
multiple interactions decreases activity |
ISO |
Chlorpromazine inhibits the reaction [SLC19A1 protein results in increased uptake of Methotrexate] Chlorpromazine results in decreased activity of SLC19A1 protein |
CTD |
PMID:17482559 |
|
NCBI chr10:76,868,103...76,886,266
Ensembl chr10:76,868,075...76,896,836
|
|
G |
Slc1a5 |
solute carrier family 1 (neutral amino acid transporter), member 5 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SLC1A5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:16,515,259...16,532,199
Ensembl chr 7:16,515,265...16,532,199
|
|
G |
Slc22a2 |
solute carrier family 22 (organic cation transporter), member 2 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr17:12,803,076...12,847,376
Ensembl chr17:12,803,019...12,847,375
|
|
G |
Slc22a7 |
solute carrier family 22 (organic anion transporter), member 7 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SLC22A7 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr17:46,743,111...46,749,403
Ensembl chr17:46,743,109...46,749,383
|
|
G |
Slc2a3 |
solute carrier family 2 (facilitated glucose transporter), member 3 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 6:122,704,783...122,779,149
Ensembl chr 6:122,704,768...122,778,599
|
|
G |
Slc31a1 |
solute carrier family 31, member 1 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Copper affects the localization of SLC31A1 protein] |
CTD |
PMID:12501239 |
|
NCBI chr 4:62,278,821...62,310,006
Ensembl chr 4:62,278,964...62,310,006
|
|
G |
Slc3a2 |
solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SLC3A2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:8,684,931...8,700,733
Ensembl chr19:8,684,246...8,700,733
|
|
G |
Slc51b |
solute carrier family 51, beta subunit |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SLC51B mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 9:65,320,035...65,330,055
Ensembl chr 9:65,319,996...65,330,237
|
|
G |
Slc6a6 |
solute carrier family 6 (neurotransmitter transporter, taurine), member 6 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SLC6A6 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:91,661,031...91,736,044
Ensembl chr 6:91,661,034...91,736,047
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SLCO2B1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:99,307,011...99,360,547
Ensembl chr 7:99,307,011...99,360,547
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Copper inhibits the reaction [Trientine results in decreased activity of SOD1 protein]] |
CTD |
PMID:22362149 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sox2 |
SRY (sex determining region Y)-box 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SOX2 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 3:34,704,144...34,706,610
Ensembl chr 3:34,704,554...34,706,610
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SPP1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
|
|
G |
Spsb1 |
splA/ryanodine receptor domain and SOCS box containing 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SPSB1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:149,980,740...150,039,494
Ensembl chr 4:149,980,740...150,039,500
|
|
G |
Src |
Rous sarcoma oncogene |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of SRC protein] |
CTD |
PMID:29702141 |
|
NCBI chr 2:157,265,828...157,313,758
Ensembl chr 2:157,260,364...157,313,782
|
|
G |
Srebf2 |
sterol regulatory element binding factor 2 |
multiple interactions |
ISO |
Chlorpromazine results in increased cleavage of and results in increased activity of SREBF2 protein |
CTD |
PMID:17052361 |
|
NCBI chr15:82,031,455...82,089,580
Ensembl chr15:82,031,382...82,089,580
|
|
G |
Strbp |
spermatid perinuclear RNA binding protein |
increases expression |
ISO |
Chlorpromazine results in increased expression of STRBP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:37,459,880...37,593,890
Ensembl chr 2:37,373,240...37,593,871
|
|
G |
Sts |
steroid sulfatase |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Tretinoin results in increased activity of STS protein] |
CTD |
PMID:16178010 |
|
NCBI chr X:168,856,332...169,015,037
|
|
G |
Tagln |
transgelin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of TAGLN mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 9:45,840,926...45,847,356
Ensembl chr 9:45,840,917...45,847,356
|
|
G |
Tfdp1 |
transcription factor Dp 1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of TFDP1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 8:13,388,273...13,428,448
Ensembl chr 8:13,388,751...13,428,448
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
increases expression |
ISO |
Chlorpromazine results in increased expression of TIPARP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:65,435,868...65,462,939
Ensembl chr 3:65,435,831...65,462,939
|
|
G |
Tirap |
toll-interleukin 1 receptor (TIR) domain-containing adaptor protein |
multiple interactions |
EXP |
TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]]; TIRAP protein results in increased susceptibility to [Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4]; TIRAP protein results in increased susceptibility to [Chlorpromazine co-treated with lipoteichoic acid] |
CTD |
PMID:23238562 |
|
NCBI chr 9:35,095,687...35,111,587
Ensembl chr 9:35,095,847...35,111,587
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression increases response to substance multiple interactions |
ISO EXP |
Chlorpromazine analog results in decreased expression of TNF protein; Chlorpromazine results in decreased expression of TNF mRNA TNF protein results in increased susceptibility to Chlorpromazine [Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; [Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein; Chlorpromazine inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride]; Chlorpromazine inhibits the reaction [hydroquinone results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased susceptibility to Chlorpromazine]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein] [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine; Chlorpromazine results in decreased expression of and results in decreased activity of TNF protein |
CTD |
PMID:8550079 PMID:15052360 PMID:19362101 PMID:20371967 PMID:22414385 PMID:23238562 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfaip8 |
tumor necrosis factor, alpha-induced protein 8 |
increases expression |
ISO |
Chlorpromazine results in increased expression of TNFAIP8 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:50,112,494...50,226,296
Ensembl chr18:50,112,494...50,240,240
|
|
G |
Tnfrsf14 |
tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of TNFRSF14 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 4:155,002,944...155,013,077
Ensembl chr 4:155,006,390...155,013,020
|
|
G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
decreases activity multiple interactions |
EXP |
Chlorpromazine results in decreased activity of TNFSF11; Chlorpromazine results in decreased activity of TNFSF11 protein Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CAR2 mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr14:78,514,886...78,545,483
Ensembl chr14:78,514,885...78,545,483
|
|
G |
Trafd1 |
TRAF type zinc finger domain containing 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of TRAFD1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:121,509,788...121,524,543
Ensembl chr 5:121,509,788...121,523,695
|
|
G |
Trf |
transferrin |
affects localization |
ISO |
Chlorpromazine affects the localization of TF protein |
CTD |
PMID:12501239 |
|
NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643
|
|
G |
Trp53 |
transformation related protein 53 |
affects activity |
ISO |
Chlorpromazine affects the activity of TP53 protein |
CTD |
PMID:25596134 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Tuba1a |
tubulin, alpha 1A |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of TUBA1A mRNA |
CTD |
PMID:27015953 |
|
NCBI chr15:98,847,728...98,851,382
Ensembl chr15:98,847,718...98,851,584
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of TXN1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:57,943,373...57,956,411
Ensembl chr 4:57,943,373...57,956,411
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of TXNRD1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546
|
|
G |
Tyr |
tyrosinase |
increases expression |
ISO |
Chlorpromazine results in increased expression of TYR protein |
CTD |
PMID:25449126 |
|
NCBI chr 7:87,073,979...87,142,637
Ensembl chr 7:87,073,979...87,142,720
|
|
G |
Ung |
uracil DNA glycosylase |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of UNG mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 5:114,268,427...114,277,382
Ensembl chr 5:114,268,447...114,277,384
|
|
G |
Unkl |
unkempt family like zinc finger |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of UNKL mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:25,407,336...25,453,417
Ensembl chr17:25,407,371...25,453,417
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of VEGFA mRNA |
CTD |
PMID:15924885 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vegfb |
vascular endothelial growth factor B |
increases expression |
ISO |
Chlorpromazine results in increased expression of VEGFB mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:6,959,840...6,965,019
Ensembl chr19:6,959,841...6,965,019
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of WARS1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:108,825,956...108,860,095
Ensembl chr12:108,825,956...108,860,100
|
|
G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of WIPI1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr11:109,464,347...109,502,215
Ensembl chr11:109,464,157...109,502,793
|
|
G |
Xbp1 |
X-box binding protein 1 |
affects activity decreases expression |
ISO |
Chlorpromazine affects the activity of XBP1 protein Chlorpromazine results in decreased expression of XBP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893
|
|
G |
Xpc |
xeroderma pigmentosum, complementation group C |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of XPC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:91,466,287...91,492,870
Ensembl chr 6:91,466,287...91,492,870
|
|
G |
Xrcc4 |
X-ray repair complementing defective repair in Chinese hamster cells 4 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of XRCC4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr13:89,997,033...90,237,727
Ensembl chr13:89,922,146...90,237,727
|
|
G |
Yap1 |
yes-associated protein 1 |
multiple interactions |
ISO |
Chlorpromazine results in decreased expression of and results in increased phosphorylation of and affects the localization of YAP1 protein |
CTD |
PMID:30703373 |
|
NCBI chr 9:7,932,000...8,004,890
Ensembl chr 9:7,932,000...8,004,597
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases activity |
ISO |
Clopenthixol results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
|
G |
A930009A15Rik |
RIKEN cDNA A930009A15 gene |
decreases expression |
ISO |
Clozapine results in decreased expression of DCD protein |
CTD |
PMID:34122009 |
|
NCBI chr10:115,399,555...115,418,359
Ensembl chr10:115,405,891...115,418,353
|
|
G |
Aars |
alanyl-tRNA synthetase |
increases expression |
ISO |
Clozapine results in increased expression of AARS protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:111,759,781...111,784,237
Ensembl chr 8:111,759,776...111,784,296
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B (MDR/TAP), member 11 |
decreases activity |
ISO |
Clozapine results in decreased activity of ABCB11 protein |
CTD |
PMID:22646477 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,960
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
decreases activity multiple interactions |
ISO |
Clozapine results in decreased activity of ABCB1 protein Clozapine inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein]; Clozapine inhibits the reaction [N-n-propylnorapomorphine results in increased expression of ABCB1 protein]; Clozapine inhibits the reaction [Quinpirole results in increased expression of ABCB1 protein] |
CTD |
PMID:9111066 PMID:16810505 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B (MDR/TAP), member 1B |
multiple interactions |
ISO |
Clozapine inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Clozapine inhibits the reaction [N-n-propylnorapomorphine results in increased activity of ABCB1B promoter]; Clozapine inhibits the reaction [Quinpirole results in increased activity of ABCB1B promoter] |
CTD |
PMID:9111066 |
|
NCBI chr 5:8,848,147...8,916,314
Ensembl chr 5:8,848,147...8,916,315
|
|
G |
Abce1 |
ATP-binding cassette, sub-family E (OABP), member 1 |
increases expression |
ISO |
Clozapine results in increased expression of ABCE1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:80,410,071...80,438,369
Ensembl chr 8:80,410,091...80,438,369
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
Clozapine results in increased expression of ABCG1 mRNA |
CTD |
PMID:17346280 |
|
NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
multiple interactions |
ISO |
Clozapine inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661
|
|
G |
Ablim2 |
actin-binding LIM protein 2 |
increases expression |
ISO |
Clozapine results in increased expression of ABLIM2 mRNA |
CTD |
PMID:17346280 |
|
NCBI chr 5:35,915,200...36,042,323
Ensembl chr 5:35,915,224...36,042,317
|
|
G |
Acat2 |
acetyl-Coenzyme A acetyltransferase 2 |
increases expression |
ISO |
Clozapine results in increased expression of ACAT2 mRNA |
CTD |
PMID:17052361 |
|
NCBI chr17:13,161,929...13,179,612
Ensembl chr17:13,161,777...13,179,634
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
increases expression |
ISO |
Clozapine results in increased expression of ACOT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:84,034,635...84,040,651
Ensembl chr12:84,034,635...84,040,647
|
|
G |
Acot7 |
acyl-CoA thioesterase 7 |
decreases expression |
ISO |
Clozapine results in decreased expression of ACOT7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:152,258,872...152,356,312
Ensembl chr 4:152,262,591...152,356,312
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
multiple interactions |
ISO |
[Clozapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased activity of ACOX1 protein; [Clozapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased expression of ACOX1 mRNA |
CTD |
PMID:23226405 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
Clozapine results in decreased expression of ACTB protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:142,888,870...142,892,509
Ensembl chr 5:142,888,870...142,892,509
|
|
G |
Actbl2 |
actin, beta-like 2 |
increases expression |
ISO |
Clozapine results in increased expression of ACTBL2 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:111,391,547...111,394,283
Ensembl chr13:111,391,547...111,394,283
|
|
G |
Actr3 |
ARP3 actin-related protein 3 |
decreases expression |
ISO |
Clozapine results in decreased expression of ACTR3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:125,320,642...125,363,464
Ensembl chr 1:125,320,642...125,363,464
|
|
G |
Actr5 |
ARP5 actin-related protein 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in increased expression of ACTR5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:158,466,800...158,481,131
Ensembl chr 2:158,466,808...158,481,131
|
|
G |
Adam1a |
a disintegrin and metallopeptidase domain 1a |
decreases expression |
ISO |
Clozapine results in decreased expression of ADAM1A mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 5:121,656,667...121,659,758
Ensembl chr 5:121,656,639...121,660,134
|
|
G |
Adamts12 |
a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 12 |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in decreased expression of ADAMTS12 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:11,064,781...11,349,321
Ensembl chr15:11,064,876...11,349,317
|
|
G |
Adcy5 |
adenylate cyclase 5 |
affects response to substance multiple interactions |
EXP |
ADCY5 protein affects the susceptibility to Clozapine SCH 23390 inhibits the reaction [ADCY5 protein affects the susceptibility to Clozapine] |
CTD |
PMID:12223546 |
|
NCBI chr16:34,974,933...35,126,108
Ensembl chr16:34,975,247...35,126,108
|
|
G |
Adh5 |
alcohol dehydrogenase 5 (class III), chi polypeptide |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in increased expression of ADH5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:138,142,961...138,161,260
Ensembl chr 3:138,148,854...138,161,260
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression increases expression multiple interactions |
ISO EXP |
Clozapine results in decreased expression of ADIPOQ protein Clozapine results in increased expression of ADIPOQ protein Clozapine results in increased expression of ADIPOQ mRNA Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA] |
CTD |
PMID:17933447 PMID:18162013 PMID:20564506 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Adora2a |
adenosine A2a receptor |
decreases expression |
EXP |
Clozapine results in decreased expression of ADORA2A mRNA |
CTD |
PMID:17266109 |
|
NCBI chr10:75,152,711...75,170,626
Ensembl chr10:75,152,711...75,170,618
|
|
G |
Adra1a |
adrenergic receptor, alpha 1a |
multiple interactions |
ISO |
Clozapine binds to and results in decreased activity of ADRA1A protein |
CTD |
PMID:16545797 |
|
NCBI chr14:66,872,700...67,008,689
Ensembl chr14:66,872,700...67,008,617
|
|
G |
Agpat1 |
1-acylglycerol-3-phosphate O-acyltransferase 1 (lysophosphatidic acid acyltransferase, alpha) |
decreases expression |
EXP |
Clozapine results in decreased expression of AGPAT1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr17:34,823,164...34,832,392
Ensembl chr17:34,823,236...34,832,423
|
|
G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
multiple interactions |
ISO |
Clozapine inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Clozapine promotes the reaction [Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]] |
CTD |
PMID:11549694 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Aimp1 |
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 |
increases expression |
ISO |
Clozapine results in increased expression of AIMP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:132,366,259...132,390,151
Ensembl chr 3:132,366,242...132,390,131
|
|
G |
Ak1 |
adenylate kinase 1 |
decreases expression |
ISO |
Clozapine results in decreased expression of AK1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:32,511,770...32,525,070
Ensembl chr 2:32,511,770...32,525,070
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
increases expression decreases expression increases phosphorylation |
ISO |
Clozapine results in increased expression of AKT1 mRNA; Clozapine results in increased expression of AKT1 protein Clozapine results in decreased expression of AKT1 mRNA Clozapine results in increased phosphorylation of AKT1 protein |
CTD |
PMID:15860345 PMID:19440698 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Akt2 |
thymoma viral proto-oncogene 2 |
increases expression |
ISO |
Clozapine results in increased expression of AKT2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:27,290,977...27,340,251
Ensembl chr 7:27,290,977...27,340,251
|
|
G |
Alb |
albumin |
multiple interactions affects binding |
ISO |
Clozapine results in decreased expression of and results in decreased reduction of ALB protein [[[stearic acid binds to ALB protein] which affects the susceptibility to Clozapine] which affects the reduction of Cysteine] which affects the activity of ALB protein; [[stearic acid binds to ALB protein] which affects the susceptibility to Clozapine] which affects the reduction of Cysteine; [stearic acid binds to ALB protein] which affects the susceptibility to Clozapine; stearic acid inhibits the reaction [Clozapine binds to ALB protein] |
CTD |
PMID:31400341 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase family 1, subfamily A1 |
increases expression |
EXP |
Clozapine results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:17266109 |
|
NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829
|
|
G |
Aldob |
aldolase B, fructose-bisphosphate |
increases expression decreases expression |
ISO |
Clozapine results in increased expression of ALDOB protein Clozapine results in decreased expression of ALDOB protein |
CTD |
PMID:34122009 PMID:36482696 |
|
NCBI chr 4:49,535,993...49,549,546
Ensembl chr 4:49,535,995...49,549,546
|
|
G |
Aldoc |
aldolase C, fructose-bisphosphate |
decreases expression increases expression |
EXP ISO |
Clozapine results in decreased expression of ALDOC mRNA Clozapine results in increased expression of ALDOC mRNA |
CTD |
PMID:15860345 PMID:16465460 |
|
NCBI chr11:78,213,899...78,218,607
Ensembl chr11:78,213,794...78,218,607
|
|
G |
Alyref |
Aly/REF export factor |
decreases expression |
ISO |
Clozapine results in decreased expression of ALYREF protein |
CTD |
PMID:34122009 |
|
NCBI chr11:120,485,330...120,489,342
Ensembl chr11:120,482,947...120,489,191
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
ISO |
Clozapine results in decreased expression of ANXA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
ISO |
Clozapine results in decreased expression of ANXA5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:36,503,072...36,530,036
Ensembl chr 3:36,503,072...36,530,043
|
|
G |
Anxa6 |
annexin A6 |
decreases expression |
ISO |
Clozapine results in decreased expression of ANXA6 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:54,869,779...54,924,297
Ensembl chr11:54,869,934...54,924,271
|
|
G |
Ap1s1 |
adaptor protein complex AP-1, sigma 1 |
decreases expression |
ISO |
Clozapine results in decreased expression of AP1S1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 5:137,063,847...137,074,962
Ensembl chr 5:137,063,847...137,074,989
|
|
G |
Ap2b1 |
adaptor-related protein complex 2, beta 1 subunit |
increases expression |
ISO |
Clozapine results in increased expression of AP2B1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr11:83,189,545...83,295,861
Ensembl chr11:83,189,850...83,295,861
|
|
G |
Ap3b1 |
adaptor-related protein complex 3, beta 1 subunit |
increases expression |
ISO |
Clozapine results in increased expression of AP3B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:94,492,332...94,702,838
Ensembl chr13:94,495,468...94,702,825
|
|
G |
Apoa5 |
apolipoprotein A-V |
affects response to substance |
ISO |
APOA5 gene polymorphism affects the susceptibility to Clozapine |
CTD |
PMID:17726453 |
|
NCBI chr 9:46,179,906...46,183,219
Ensembl chr 9:46,179,931...46,183,217
|
|
G |
Apod |
apolipoprotein D |
increases expression |
EXP |
Clozapine results in increased expression of APOD mRNA; Clozapine results in increased expression of APOD protein |
CTD |
PMID:11158250 PMID:14647396 PMID:17266109 |
|
NCBI chr16:31,115,010...31,133,626
Ensembl chr16:31,115,010...31,133,626
|
|
G |
App |
amyloid beta (A4) precursor protein |
increases expression |
ISO |
Clozapine results in increased expression of APP protein |
CTD |
PMID:36482696 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Arc |
activity regulated cytoskeletal-associated protein |
decreases expression |
ISO |
Clozapine results in decreased expression of ARC mRNA |
CTD |
PMID:18208916 |
|
NCBI chr15:74,540,930...74,544,419
Ensembl chr15:74,540,932...74,544,419
|
|
G |
Arhgef9 |
CDC42 guanine nucleotide exchange factor (GEF) 9 |
decreases expression |
EXP |
Clozapine results in decreased expression of ARHGEF9 mRNA |
CTD |
PMID:17266109 |
|
NCBI chr X:94,092,536...94,240,801
Ensembl chr X:94,092,541...94,240,462
|
|
G |
Arl8a |
ADP-ribosylation factor-like 8A |
decreases expression |
ISO |
Clozapine results in decreased expression of ARL8A protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:135,074,572...135,084,007
Ensembl chr 1:135,074,562...135,084,007
|
|
G |
Armt1 |
acidic residue methyltransferase 1 |
increases expression |
ISO |
Clozapine results in increased expression of ARMT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:4,382,572...4,405,140
Ensembl chr10:4,382,467...4,405,141
|
|
G |
Arpc4 |
actin related protein 2/3 complex, subunit 4 |
affects expression |
EXP |
Clozapine affects the expression of ARPC4 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 6:113,355,074...113,367,408
Ensembl chr 6:113,355,076...113,367,409
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
ISO |
Clozapine results in increased expression of ASAH1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 8:41,793,683...41,850,681
Ensembl chr 8:41,793,234...41,827,810
|
|
G |
Asns |
asparagine synthetase |
increases expression |
ISO |
Clozapine results in increased expression of ASNS mRNA; Clozapine results in increased expression of ASNS protein |
CTD |
PMID:15342952 PMID:17175557 PMID:36482696 |
|
NCBI chr 6:7,675,169...7,693,209
Ensembl chr 6:7,675,169...7,693,254
|
|
G |
Asph |
aspartate-beta-hydroxylase |
increases expression |
ISO |
Clozapine results in increased expression of ASPH protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:9,449,085...9,669,344
Ensembl chr 4:9,448,069...9,669,344
|
|
G |
Ass1 |
argininosuccinate synthetase 1 |
increases expression |
ISO |
Clozapine results in increased expression of ASS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:31,360,282...31,410,682
Ensembl chr 2:31,360,219...31,410,684
|
|
G |
Atad3a |
ATPase family, AAA domain containing 3A |
decreases expression |
ISO |
Clozapine results in decreased expression of ATAD3A protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:155,825,097...155,845,579
Ensembl chr 4:155,825,098...155,845,550
|
|
G |
Atp2a3 |
ATPase, Ca++ transporting, ubiquitous |
increases expression |
ISO |
Clozapine results in increased expression of ATP2A3 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:72,851,995...72,883,869
Ensembl chr11:72,851,995...72,883,870
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
decreases expression |
ISO |
Clozapine results in decreased expression of ATP5F1B protein |
CTD |
PMID:19441803 |
|
NCBI chr10:127,919,176...127,926,257
Ensembl chr10:127,919,142...127,926,260
|
|
G |
Atp5pb |
ATP synthase peripheral stalk-membrane subunit b |
increases expression |
ISO |
Clozapine results in increased expression of ATP5F1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:105,850,014...105,866,579
Ensembl chr 3:105,850,014...105,867,415
|
|
G |
Atp6v1a |
ATPase, H+ transporting, lysosomal V1 subunit A |
decreases expression |
ISO |
Clozapine results in decreased expression of ATP6V1A protein |
CTD |
PMID:34122009 |
|
NCBI chr16:43,905,765...43,960,055
Ensembl chr16:43,905,765...43,960,068
|
|
G |
Atp6v1b1 |
ATPase, H+ transporting, lysosomal V1 subunit B1 |
decreases expression |
ISO |
Clozapine results in decreased expression of ATP6V1B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:83,719,999...83,735,837
Ensembl chr 6:83,719,972...83,735,837
|
|
G |
Atp6v1b2 |
ATPase, H+ transporting, lysosomal V1 subunit B2 |
decreases expression |
ISO |
Clozapine results in decreased expression of ATP6V1B2 protein |
CTD |
PMID:19441803 PMID:34122009 |
|
NCBI chr 8:69,541,388...69,566,370
Ensembl chr 8:69,541,298...69,566,363
|
|
G |
Atxn10 |
ataxin 10 |
increases expression |
ISO |
Clozapine results in increased expression of ATXN10 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:85,220,456...85,348,038
Ensembl chr15:85,220,446...85,347,413
|
|
G |
Axin2 |
axin 2 |
decreases expression |
ISO |
Clozapine results in decreased expression of AXIN2 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr11:108,808,687...108,841,609
Ensembl chr11:108,811,175...108,841,609
|
|
G |
Bace2 |
beta-site APP-cleaving enzyme 2 |
increases expression |
ISO |
Clozapine results in increased expression of BACE2 protein |
CTD |
PMID:36482696 |
|
NCBI chr16:97,157,928...97,244,136
Ensembl chr16:97,157,942...97,244,136
|
|
G |
Bax |
BCL2-associated X protein |
increases expression multiple interactions decreases expression |
ISO |
Clozapine results in increased expression of BAX mRNA; Clozapine results in increased expression of BAX protein CSF3 protein inhibits the reaction [Clozapine results in increased expression of BAX mRNA] Clozapine results in decreased expression of BAX protein |
CTD |
PMID:16160616 PMID:17069804 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Baz1b |
bromodomain adjacent to zinc finger domain, 1B |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in decreased expression of BAZ1B protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:135,214,094...135,274,985
Ensembl chr 5:135,216,118...135,274,983
|
|
G |
Bcar1 |
breast cancer anti-estrogen resistance 1 |
decreases expression |
ISO |
Clozapine results in decreased expression of BCAR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:112,437,106...112,470,481
Ensembl chr 8:112,437,106...112,470,441
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
increases expression |
ISO |
Clozapine results in increased expression of BCL2 mRNA; Clozapine results in increased expression of BCL2 protein |
CTD |
PMID:15126120 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l14 |
BCL2-like 14 (apoptosis facilitator) |
decreases expression |
ISO |
Clozapine results in decreased expression of BCL2L14 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:134,373,292...134,415,687
Ensembl chr 6:134,373,281...134,415,699
|
|
G |
Bdnf |
brain derived neurotrophic factor |
decreases expression increases expression |
ISO |
Clozapine results in decreased expression of BDNF mRNA Clozapine results in increased expression of BDNF mRNA; Clozapine results in increased expression of BDNF protein |
CTD |
PMID:11488957 PMID:12478621 PMID:17442489 |
|
NCBI chr 2:109,505,045...109,557,388
Ensembl chr 2:109,505,045...109,557,352
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein like |
decreases expression |
ISO |
Clozapine results in decreased expression of BET1L mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:140,433,297...140,437,306
Ensembl chr 7:140,433,307...140,437,490
|
|
G |
Bik |
BCL2-interacting killer |
multiple interactions increases expression |
ISO |
CSF3 protein inhibits the reaction [Clozapine results in increased expression of BIK mRNA] |
CTD |
PMID:16160616 |
|
NCBI chr15:83,410,992...83,428,836
Ensembl chr15:83,411,063...83,428,835
|
|
G |
Bptf |
bromodomain PHD finger transcription factor |
decreases expression |
EXP |
Clozapine results in decreased expression of BPTF mRNA |
CTD |
PMID:14647396 |
|
NCBI chr11:106,923,907...107,022,982
Ensembl chr11:106,923,907...107,022,953
|
|
G |
Bzw1 |
basic leucine zipper and W2 domains 1 |
increases expression |
ISO |
Clozapine results in increased expression of BZW1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:58,432,057...58,446,513
Ensembl chr 1:58,432,057...58,446,512
|
|
G |
Cacna1a |
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
decreases expression |
EXP ISO |
Clozapine results in decreased expression of CACNA1A mRNA |
CTD |
PMID:14647396 PMID:16715494 |
|
NCBI chr 8:85,065,257...85,366,880
Ensembl chr 8:85,065,268...85,366,875
|
|
G |
Calcoco1 |
calcium binding and coiled coil domain 1 |
increases expression |
ISO |
Clozapine results in increased expression of CALCOCO1 protein |
CTD |
PMID:36482696 |
|
NCBI chr15:102,615,212...102,630,616
Ensembl chr15:102,615,212...102,630,613
|
|
G |
Calm2 |
calmodulin 2 |
increases expression |
ISO |
Clozapine results in increased expression of CALM2 mRNA |
CTD |
PMID:19289156 |
|
NCBI chr17:87,740,829...87,754,363
Ensembl chr17:87,740,840...87,754,363
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Clozapine results in decreased expression of CALR protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Calu |
calumenin |
decreases expression |
ISO |
Clozapine results in decreased expression of CALU protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:29,348,105...29,376,674
Ensembl chr 6:29,348,068...29,377,109
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
decreases expression increases expression |
EXP ISO |
Clozapine results in decreased expression of CAMK2A mRNA Clozapine results in increased expression of CAMK2A mRNA Clozapine results in decreased expression of CAMK2A protein |
CTD |
PMID:15860345 PMID:17266109 PMID:19289156 |
|
NCBI chr18:61,058,704...61,121,224
Ensembl chr18:61,058,690...61,121,224
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II, beta |
decreases expression |
ISO |
Clozapine results in decreased expression of CAMK2B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr11:5,919,642...6,016,401
Ensembl chr11:5,919,644...6,016,362
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II, delta |
decreases expression |
ISO |
Clozapine results in decreased expression of CAMK2D mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:126,389,136...126,639,975
Ensembl chr 3:126,389,951...126,639,975
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
increases expression decreases expression |
ISO |
Clozapine results in increased expression of CAMK4 mRNA Clozapine results in decreased expression of CAMK4 protein |
CTD |
PMID:15860345 PMID:19289156 |
|
NCBI chr18:33,067,995...33,328,820
Ensembl chr18:33,067,984...33,324,281
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1, alpha |
decreases expression |
ISO |
Clozapine results in decreased expression of CAMKK1 protein |
CTD |
PMID:19289156 |
|
NCBI chr11:72,906,869...72,932,899
Ensembl chr11:72,909,834...72,932,899
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2, beta |
decreases expression |
ISO |
Clozapine results in decreased expression of CAMKK2 protein |
CTD |
PMID:19289156 |
|
NCBI chr 5:122,856,064...122,918,295
Ensembl chr 5:122,869,233...122,917,472
|
|
G |
Canx |
calnexin |
decreases expression |
ISO |
Clozapine results in decreased expression of CANX protein |
CTD |
PMID:34122009 |
|
NCBI chr11:50,184,784...50,216,500
Ensembl chr11:50,184,788...50,216,500
|
|
G |
Cars |
cysteinyl-tRNA synthetase |
increases expression |
ISO |
Clozapine results in increased expression of CARS protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:143,110,967...143,153,827
Ensembl chr 7:143,110,967...143,153,827
|
|
G |
Cartpt |
CART prepropeptide |
decreases expression |
ISO |
Clozapine results in decreased expression of CARTPT mRNA |
CTD |
PMID:14696011 |
|
NCBI chr13:100,034,991...100,037,191
Ensembl chr13:100,034,997...100,037,599
|
|
G |
Casp1 |
caspase 1 |
increases activity |
ISO |
Clozapine results in increased activity of CASP1 protein |
CTD |
PMID:34935985 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
Clozapine results in increased activity of CASP3 protein Palmitic Acid promotes the reaction [Clozapine results in increased activity of CASP3 protein] |
CTD |
PMID:22700542 PMID:24709159 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp7 |
caspase 7 |
increases activity multiple interactions |
ISO |
Clozapine results in increased activity of CASP7 protein Palmitic Acid promotes the reaction [Clozapine results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Clozapine inhibits the reaction [Corticosterone results in increased activity of CAT protein]; Clozapine inhibits the reaction [Lipopolysaccharides inhibits the reaction [Corticosterone results in increased activity of CAT protein]] |
CTD |
PMID:14730115 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
Clozapine results in increased expression of CCAR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:62,579,707...62,628,147
Ensembl chr10:62,579,707...62,628,065
|
|
G |
Ccdc47 |
coiled-coil domain containing 47 |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Clozapine] results in increased expression of CCDC47 protein Clozapine results in increased expression of CCDC47 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:106,090,086...106,107,349
Ensembl chr11:106,088,234...106,107,170
|
|
G |
Cck |
cholecystokinin |
multiple interactions increases expression |
ISO |
Clozapine inhibits the reaction [Dizocilpine Maleate results in decreased expression of CCK mRNA]; Clozapine inhibits the reaction [Dizocilpine Maleate results in decreased expression of CCK protein] Clozapine results in increased expression of CCK mRNA |
CTD |
PMID:10974607 PMID:16567023 |
|
NCBI chr 9:121,318,890...121,324,728
Ensembl chr 9:121,318,890...121,324,760
|
|
G |
Cckbr |
cholecystokinin B receptor |
increases expression |
EXP |
Clozapine results in increased expression of CCKBR mRNA |
CTD |
PMID:17266109 |
|
NCBI chr 7:105,075,201...105,085,546
Ensembl chr 7:105,074,938...105,120,105
|
|
G |
Ccl1 |
chemokine (C-C motif) ligand 1 |
decreases expression |
ISO |
Clozapine results in decreased expression of CCL1 mRNA |
CTD |
PMID:17346280 |
|
NCBI chr11:82,067,492...82,070,638
Ensembl chr11:82,067,483...82,196,516
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Clozapine results in decreased expression of CCND1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
ISO |
Clozapine results in increased expression of CCND3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr17:47,815,976...47,910,614
Ensembl chr17:47,815,976...47,910,616
|
|
G |
Ccnl1 |
cyclin L1 |
increases expression |
ISO |
Clozapine results in increased expression of CCNL1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:65,853,333...65,869,451
Ensembl chr 3:65,853,572...65,865,670
|
|
G |
Cct7 |
chaperonin containing Tcp1, subunit 7 (eta) |
decreases expression |
ISO |
Clozapine results in decreased expression of CCT7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:85,428,487...85,445,459
Ensembl chr 6:85,428,496...85,445,457
|
|
G |
Cd276 |
CD276 antigen |
decreases expression |
ISO |
Clozapine results in decreased expression of CD276 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:58,431,583...58,462,316
Ensembl chr 9:58,431,581...58,462,720
|
|
G |
Cd63 |
CD63 antigen |
increases expression |
ISO |
Clozapine results in increased expression of CD63 protein |
CTD |
PMID:36482696 |
|
NCBI chr10:128,731,577...128,748,691
Ensembl chr10:128,736,858...128,748,691
|
|
G |
Cdipt |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase (phosphatidylinositol synthase) |
increases expression |
ISO |
Clozapine results in increased expression of CDIPT protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:126,575,630...126,579,671
Ensembl chr 7:126,575,086...126,579,673
|
|
G |
Cdk4 |
cyclin dependent kinase 4 |
increases expression |
ISO |
Clozapine results in increased expression of CDK4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:126,899,404...126,903,157
Ensembl chr10:126,899,403...126,903,789
|
|
G |
Cdk5 |
cyclin dependent kinase 5 |
increases expression |
ISO |
Clozapine results in increased expression of CDK5 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:24,612,595...24,628,737
Ensembl chr 5:24,623,239...24,628,528
|
|
G |
Cdk5r1 |
cyclin dependent kinase 5, regulatory subunit 1 (p35) |
increases expression |
EXP |
Clozapine results in increased expression of CDK5R1 mRNA |
CTD |
PMID:17266109 |
|
NCBI chr11:80,367,849...80,372,010
Ensembl chr11:80,367,849...80,372,010
|
|
G |
Cebpa |
CCAAT/enhancer binding protein (C/EBP), alpha |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein] Clozapine results in increased expression of CEBPA mRNA; Clozapine results in increased expression of CEBPA protein |
CTD |
PMID:20564506 |
|
NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353
|
|
G |
Cenpv |
centromere protein V |
increases expression |
ISO |
Clozapine results in increased expression of CENPV protein |
CTD |
PMID:34122009 |
|
NCBI chr11:62,415,770...62,430,695
Ensembl chr11:62,415,772...62,430,087
|
|
G |
Cfap210 |
cilia and flagella associated protein 210 |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in increased expression of CFAP210 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:69,587,736...69,619,873
Ensembl chr 2:69,588,377...69,619,919
|
|
G |
Chchd2 |
coiled-coil-helix-coiled-coil-helix domain containing 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in increased expression of CHCHD2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:129,910,002...129,916,311
Ensembl chr 5:129,909,997...129,916,311
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
decreases expression |
ISO |
Clozapine results in decreased expression of CHD4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:125,073,144...125,107,554
Ensembl chr 6:125,072,944...125,107,554
|
|
G |
Chga |
chromogranin A |
decreases expression increases expression |
ISO |
Clozapine results in decreased expression of CHGA mRNA Clozapine results in increased expression of CHGA mRNA |
CTD |
PMID:12437575 |
|
NCBI chr12:102,521,200...102,531,286
Ensembl chr12:102,521,228...102,531,287
|
|
G |
Chl1 |
cell adhesion molecule L1-like |
decreases expression |
EXP |
Clozapine results in decreased expression of CHL1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 6:103,487,372...103,709,999
Ensembl chr 6:103,487,547...103,727,172
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
EXP |
Clozapine results in decreased expression of CHN1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:73,441,004...73,605,723
Ensembl chr 2:73,441,004...73,605,690
|
|
G |
Chordc1 |
cysteine and histidine-rich domain (CHORD)-containing, zinc-binding protein 1 |
increases expression |
ISO |
Clozapine results in increased expression of CHORDC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:18,203,563...18,225,296
Ensembl chr 9:18,203,421...18,228,738
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1, CNS |
affects binding increases expression multiple interactions |
ISO |
Clozapine analog binds to CHRM1 protein; Clozapine binds to CHRM1 protein Clozapine results in increased expression of CHRM1 protein Clozapine inhibits the reaction [Dextroamphetamine results in decreased expression of CHRM1 protein] |
CTD |
PMID:11997696 PMID:16983399 PMID:18806925 |
|
NCBI chr19:8,641,369...8,660,970
Ensembl chr19:8,641,153...8,660,951
|
|
G |
Ckap4 |
cytoskeleton-associated protein 4 |
increases expression |
ISO |
Clozapine results in increased expression of CKAP4 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:84,362,169...84,369,752
Ensembl chr10:84,362,169...84,369,926
|
|
G |
Clic1 |
chloride intracellular channel 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in decreased expression of CLIC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:35,269,219...35,277,695
Ensembl chr17:35,268,942...35,277,725
|
|
G |
Clic4 |
chloride intracellular channel 4 (mitochondrial) |
increases expression |
ISO |
Clozapine results in increased expression of CLIC4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:134,941,280...135,000,071
Ensembl chr 4:134,941,280...135,000,125
|
|
G |
Clock |
circadian locomotor output cycles kaput |
affects response to substance |
ISO |
CLOCK gene SNP affects the susceptibility to Clozapine |
CTD |
PMID:15331141 |
|
NCBI chr 5:76,357,715...76,452,675
Ensembl chr 5:76,357,715...76,452,639
|
|
G |
Clta |
clathrin, light polypeptide (Lca) |
decreases expression |
ISO |
Clozapine results in decreased expression of CLTA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:44,003,816...44,032,846
Ensembl chr 4:44,004,452...44,032,846
|
|
G |
Cltb |
clathrin, light polypeptide (Lcb) |
decreases expression |
ISO |
Clozapine results in decreased expression of CLTB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:54,740,199...54,759,186
Ensembl chr13:54,740,214...54,759,157
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
decreases expression increases expression |
EXP ISO |
Clozapine results in decreased expression of CNP mRNA Clozapine results in decreased expression of CNP protein Clozapine results in increased expression of CNP mRNA |
CTD |
PMID:17266109 PMID:34122009 |
|
NCBI chr11:100,465,765...100,472,565
Ensembl chr11:100,465,730...100,482,555
|
|
G |
Coil |
coilin |
increases expression |
ISO |
Clozapine results in increased expression of COIL mRNA |
CTD |
PMID:16715494 |
|
NCBI chr11:88,864,761...88,882,439
Ensembl chr11:88,861,078...88,882,439
|
|
G |
Col5a2 |
collagen, type V, alpha 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in increased expression of COL5A2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:45,413,491...45,542,442
Ensembl chr 1:45,413,481...45,542,442
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions affects response to substance increases response to substance |
ISO |
[tolcapone results in decreased activity of COMT protein] promotes the reaction [Clozapine results in increased abundance of Dopamine] COMT protein affects the susceptibility to Clozapine COMT gene polymorphism results in increased susceptibility to Clozapine |
CTD |
PMID:15190105 PMID:17123785 |
|
NCBI chr16:18,225,632...18,247,006
Ensembl chr16:18,225,636...18,245,602
|
|
G |
Cops3 |
COP9 signalosome subunit 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in decreased expression of COPS3 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:59,708,621...59,739,079
Ensembl chr11:59,708,621...59,730,664
|
|
G |
Coro1b |
coronin, actin binding protein 1B |
decreases expression |
ISO |
Clozapine results in decreased expression of CORO1B protein |
CTD |
PMID:34122009 |
|
NCBI chr19:4,198,610...4,204,034
Ensembl chr19:4,198,618...4,204,034
|
|
G |
Cplx2 |
complexin 2 |
decreases expression |
EXP |
Clozapine results in decreased expression of CPLX2 mRNA |
CTD |
PMID:17266109 |
|
NCBI chr13:54,455,447...54,531,736
Ensembl chr13:54,519,162...54,531,730 Ensembl chr13:54,519,162...54,531,730
|
|
G |
Cpn1 |
carboxypeptidase N, polypeptide 1 |
increases expression |
ISO |
Clozapine results in increased expression of CPN1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr19:43,944,746...43,974,990
Ensembl chr19:43,944,746...43,974,995
|
|
G |
Cpne1 |
copine I |
decreases expression |
ISO |
Clozapine results in decreased expression of CPNE1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:155,913,765...155,953,847
Ensembl chr 2:155,913,762...155,953,885
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
[Clozapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased activity of CPT2 protein; [Clozapine co-treated with 1-(carboxymethylthio)tetradecane] results in increased expression of CPT2 mRNA |
CTD |
PMID:23226405 |
|
NCBI chr 4:107,761,179...107,780,786
Ensembl chr 4:107,761,178...107,780,807
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation |
EXP |
Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of CREB1 protein] Clozapine results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:12871586 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
ISO |
Clozapine results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 3:19,747,565...19,749,560
Ensembl chr 3:19,747,565...19,749,560
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
decreases expression |
ISO |
Clozapine results in decreased expression of CRHBP mRNA |
CTD |
PMID:16715494 |
|
NCBI chr13:95,567,884...95,581,339
Ensembl chr13:95,567,879...95,581,432
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
increases expression |
ISO |
Clozapine results in increased expression of CRP protein |
CTD |
PMID:17685758 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
multiple interactions |
ISO |
CSF3 protein inhibits the reaction [Clozapine results in increased expression of BAX mRNA]; CSF3 protein inhibits the reaction [Clozapine results in increased expression of BIK mRNA]; CSF3 protein inhibits the reaction [Clozapine results in increased expression of TP53 mRNA] |
CTD |
PMID:16160616 |
|
NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455
|
|
G |
Csnk2a1 |
casein kinase 2, alpha 1 polypeptide |
decreases expression |
ISO |
Clozapine results in decreased expression of CSNK2A1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 2:152,068,468...152,123,772
Ensembl chr 2:152,068,759...152,123,772
|
|
G |
Cst3 |
cystatin C |
increases expression |
EXP |
Clozapine results in increased expression of CST3 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612
|
|
G |
Cstf1 |
cleavage stimulation factor, 3' pre-RNA, subunit 1 |
decreases expression |
ISO |
Clozapine results in decreased expression of CSTF1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:172,212,591...172,224,369
Ensembl chr 2:172,212,601...172,224,368
|
|
G |
Cstf2 |
cleavage stimulation factor, 3' pre-RNA subunit 2 |
decreases expression |
ISO |
Clozapine results in decreased expression of CSTF2 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:132,959,925...132,987,571
Ensembl chr X:132,959,936...132,987,568
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
increases expression |
ISO |
Clozapine results in increased expression of CTBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:33,405,067...33,432,467
Ensembl chr 5:33,405,067...33,432,338
|
|
G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
increases expression multiple interactions |
ISO |
Clozapine results in increased expression of CTNNB1 protein DRD2 protein affects the reaction [Clozapine results in increased expression of CTNNB1 protein] |
CTD |
PMID:16144542 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Ctrl |
chymotrypsin-like |
increases expression |
ISO |
Clozapine results in increased expression of CTRL mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 8:106,658,626...106,660,494
Ensembl chr 8:106,658,635...106,660,494
|
|
G |
Ctsk |
cathepsin K |
increases expression |
ISO |
Clozapine results in increased expression of CTSK mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 3:95,406,521...95,416,698
Ensembl chr 3:95,406,567...95,416,673
|
|
G |
Cttn |
cortactin |
increases expression |
ISO |
Clozapine results in increased expression of CTTN protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:143,989,468...144,024,743
Ensembl chr 7:143,989,470...144,024,746
|
|
G |
Cul2 |
cullin 2 |
increases expression |
ISO |
Clozapine results in increased expression of CUL2 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:3,382,970...3,436,700
Ensembl chr18:3,382,988...3,436,377
|
|
G |
Cul3 |
cullin 3 |
increases expression |
ISO |
Clozapine results in increased expression of CUL3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:80,242,640...80,318,407
Ensembl chr 1:80,242,640...80,318,197
|
|
G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 |
decreases expression decreases secretion increases secretion multiple interactions |
ISO |
Clozapine results in decreased expression of CXCL1 mRNA Clozapine results in decreased secretion of CXCL1 protein Clozapine results in increased secretion of CXCL1 protein belnacasan inhibits the reaction [Clozapine results in increased secretion of CXCL1 protein] |
CTD |
PMID:17346280 PMID:34935985 PMID:36482696 |
|
NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
|
|
G |
Cxcl10 |
chemokine (C-X-C motif) ligand 10 |
decreases secretion |
ISO |
Clozapine results in decreased secretion of CXCL10 protein |
CTD |
PMID:36482696 |
|
NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748
|
|
G |
Cxcl15 |
chemokine (C-X-C motif) ligand 15 |
decreases secretion |
ISO |
Clozapine results in decreased secretion of CXCL8 protein |
CTD |
PMID:36482696 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl3 |
chemokine (C-X-C motif) ligand 3 |
decreases expression decreases secretion |
ISO |
Clozapine results in decreased expression of CXCL1 mRNA Clozapine results in decreased secretion of CXCL1 protein |
CTD |
PMID:17346280 PMID:36482696 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cyb5b |
cytochrome b5 type B |
increases expression |
ISO |
Clozapine results in increased expression of CYB5B mRNA |
CTD |
PMID:19441803 |
|
NCBI chr 8:107,877,293...107,914,102
Ensembl chr 8:107,877,272...107,914,103
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
increases expression |
ISO |
Clozapine results in increased expression of CYB5R1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:134,333,519...134,339,476
Ensembl chr 1:134,333,297...134,339,478
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity increases metabolic processing |
ISO |
Clozapine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Clozapine results in decreased activity of CYP1A1 protein CYP1A1 protein results in increased metabolism of Clozapine |
CTD |
PMID:18493746 PMID:18809730 PMID:33814510 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases response to substance multiple interactions increases metabolic processing increases expression affects metabolic processing affects response to substance decreases metabolic processing |
ISO EXP |
CYP1A2 gene SNP results in decreased susceptibility to Clozapine Clozapine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] CYP1A2 protein results in increased metabolism of Clozapine Clozapine results in increased expression of CYP1A2 mRNA CYP1A2 gene polymorphism affects the metabolism of Clozapine; CYP1A2 protein affects the metabolism of Clozapine; CYP1A2 protein polymorphism affects the metabolism of Clozapine [Ciprofloxacin results in decreased activity of CYP1A2 protein] which results in increased abundance of Clozapine; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Clozapine; Clozapine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]; Smoke affects the reaction [CYP1A2 gene polymorphism affects the metabolism of Clozapine]; Smoke promotes the reaction [CYP1A2 protein results in increased metabolism of Clozapine] CYP1A2 gene SNP affects the susceptibility to Clozapine; CYP1A2 protein affects the susceptibility to Clozapine CYP1A2 gene SNP results in increased metabolism of Clozapine; CYP1A2 protein results in increased metabolism of Clozapine CYP1A2 gene SNP results in decreased metabolism of Clozapine |
CTD |
PMID:11151749 PMID:11763009 PMID:12919186 PMID:12969762 PMID:15206669 PMID:15286053 PMID:15883149 PMID:15949157 PMID:16044115 PMID:18493746 PMID:18809730 PMID:23397584 PMID:27320963 More...
|
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases metabolic processing decreases activity |
ISO |
CYP1B1 protein results in increased metabolism of Clozapine Clozapine results in decreased activity of CYP1B1 protein |
CTD |
PMID:18809730 PMID:33814510 |
|
NCBI chr17:80,014,369...80,022,490
Ensembl chr17:80,008,966...80,022,490
|
|
G |
Cyp2c29 |
cytochrome P450, family 2, subfamily c, polypeptide 29 |
increases metabolic processing |
ISO |
CYP2C8 protein results in increased metabolism of Clozapine |
CTD |
PMID:18809730 PMID:27320963 |
|
NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157
|
|
G |
Cyp2c38 |
cytochrome P450, family 2, subfamily c, polypeptide 38 |
multiple interactions increases metabolic processing |
ISO |
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Clozapine CYP2C19 protein results in increased metabolism of Clozapine |
CTD |
PMID:18809730 PMID:23397584 PMID:27320963 |
|
NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
multiple interactions increases metabolic processing |
ISO |
[Clozapine results in decreased activity of CYP2C9 protein] which results in increased susceptibility to Phenytoin; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Clozapine CYP2C9 protein results in increased metabolism of Clozapine |
CTD |
PMID:17961958 PMID:18809730 PMID:23397584 |
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
G |
Cyp2c66 |
cytochrome P450, family 2, subfamily c, polypeptide 66 |
multiple interactions increases metabolic processing |
ISO |
[Clozapine results in decreased activity of CYP2C9 protein] which results in increased susceptibility to Phenytoin; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Clozapine CYP2C9 protein results in increased metabolism of Clozapine |
CTD |
PMID:17961958 PMID:18809730 PMID:23397584 |
|
NCBI chr19:39,102,342...39,175,200
Ensembl chr19:39,102,342...39,175,516
|
|
G |
Cyp2d22 |
cytochrome P450, family 2, subfamily d, polypeptide 22 |
affects metabolic processing increases metabolic processing multiple interactions |
ISO |
CYP2D6 protein affects the metabolism of Clozapine CYP2D6 protein results in increased metabolism of Clozapine [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Clozapine |
CTD |
PMID:15286053 PMID:18809730 PMID:23397584 PMID:27320963 |
|
NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
|
|
G |
Cyp2j9 |
cytochrome P450, family 2, subfamily j, polypeptide 9 |
increases metabolic processing |
ISO |
CYP2J2 protein results in increased metabolism of Clozapine |
CTD |
PMID:18809730 |
|
NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815
|
|
G |
Cyp3a11 |
cytochrome P450, family 3, subfamily a, polypeptide 11 |
increases metabolic processing |
ISO |
CYP3A5 protein results in increased metabolism of Clozapine |
CTD |
PMID:18809730 |
|
NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774
|
|
G |
Dab1 |
disabled 1 |
increases expression |
ISO |
Clozapine results in increased expression of DAB1 mRNA |
CTD |
PMID:19359144 |
|
NCBI chr 4:103,476,425...104,602,041
Ensembl chr 4:103,476,556...104,602,041
|
|
G |
Dab2 |
disabled 2, mitogen-responsive phosphoprotein |
increases expression |
ISO |
Clozapine results in increased expression of DAB2 protein |
CTD |
PMID:36482696 |
|
NCBI chr15:6,329,269...6,470,196
Ensembl chr15:6,329,269...6,470,193
|
|
G |
Daglb |
diacylglycerol lipase, beta |
increases expression |
ISO |
Clozapine results in increased expression of DAGLB protein |
CTD |
PMID:36482696 |
|
NCBI chr 5:143,450,239...143,490,197
Ensembl chr 5:143,450,339...143,491,697
|
|
G |
Dcaf6 |
DDB1 and CUL4 associated factor 6 |
decreases expression |
EXP |
Clozapine results in decreased expression of DCAF6 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:165,157,069...165,288,475
Ensembl chr 1:165,156,267...165,288,044
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
increases expression |
EXP ISO |
Clozapine results in increased expression of DCLK1 mRNA |
CTD |
PMID:15860345 PMID:18797397 |
|
NCBI chr 3:55,149,724...55,446,489
Ensembl chr 3:55,149,785...55,446,489
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions increases expression |
EXP |
Clozapine results in increased expression of and results in increased activity of DDC protein Clozapine results in increased expression of DDC mRNA |
CTD |
PMID:16415089 |
|
NCBI chr11:11,764,101...11,848,144
Ensembl chr11:11,764,101...11,848,144
|
|
G |
Ddx46 |
DEAD box helicase 46 |
increases expression |
ISO |
Clozapine results in increased expression of DDX46 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:55,782,790...55,829,080
Ensembl chr13:55,782,840...55,829,069
|
|
G |
Dennd10 |
DENN domain containing 10 |
increases expression |
ISO |
Clozapine results in increased expression of DENND10 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr19:60,800,029...60,824,673
Ensembl chr19:60,800,023...60,824,665
|
|
G |
Depp1 |
DEPP1 autophagy regulator |
increases expression |
ISO |
Clozapine results in increased expression of DEPP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 6:116,627,645...116,629,808
Ensembl chr 6:116,627,570...116,629,755
|
|
G |
Dgcr6 |
DiGeorge syndrome critical region gene 6 |
decreases expression |
ISO |
Clozapine results in decreased expression of DGCR6 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:17,870,736...17,889,497
Ensembl chr16:17,870,724...17,889,496
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
decreases expression |
ISO |
Clozapine results in decreased expression of DGKA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:128,556,000...128,581,002
Ensembl chr10:128,556,003...128,580,724
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
Clozapine results in increased expression of DHCR24 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases expression |
ISO |
Clozapine results in increased expression of DHCR7 mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147
|
|
G |
Dhx30 |
DEAH (Asp-Glu-Ala-His) box polypeptide 30 |
increases expression |
ISO |
Clozapine results in increased expression of DHX30 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:109,913,387...109,946,728
Ensembl chr 9:109,913,388...109,946,898
|
|
G |
Dhx38 |
DEAH (Asp-Glu-Ala-His) box polypeptide 38 |
decreases expression |
ISO |
Clozapine results in decreased expression of DHX38 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:110,274,631...110,292,493
Ensembl chr 8:110,274,643...110,292,493
|
|
G |
Disc1 |
disrupted in schizophrenia 1 |
decreases response to substance affects response to substance |
ISO |
DISC1 gene mutant form results in decreased susceptibility to Clozapine DISC1 protein affects the susceptibility to Clozapine |
CTD |
PMID:20531374 |
|
NCBI chr 8:125,773,928...125,991,882
Ensembl chr 8:125,780,934...125,988,597
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex) |
decreases expression increases expression |
ISO |
Clozapine results in decreased expression of DLAT mRNA Clozapine results in increased expression of DLAT protein |
CTD |
PMID:15860345 PMID:34122009 |
|
NCBI chr 9:50,545,933...50,571,080
Ensembl chr 9:50,545,933...50,571,080
|
|
G |
Dlg2 |
discs large MAGUK scaffold protein 2 |
increases expression |
ISO |
Clozapine results in increased expression of DLG2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:90,125,399...92,098,454
Ensembl chr 7:90,125,880...92,098,455
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex) |
decreases expression |
ISO |
Clozapine results in decreased expression of DLST protein |
CTD |
PMID:34122009 |
|
NCBI chr12:85,157,597...85,180,865
Ensembl chr12:85,157,607...85,181,619
|
|
G |
Dnah11 |
dynein, axonemal, heavy chain 11 |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in decreased expression of DNAH11 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:117,841,717...118,162,778
Ensembl chr12:117,841,717...118,162,778
|
|
G |
Dnaja3 |
DnaJ heat shock protein family (Hsp40) member A3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in increased expression of DNAJA3 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:4,501,934...4,525,559
Ensembl chr16:4,457,853...4,525,559
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
increases expression |
ISO |
Clozapine results in increased expression of DNAJB11 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:22,676,595...22,698,384
Ensembl chr16:22,676,595...22,698,384
|
|
G |
Dpf1 |
double PHD fingers 1 |
affects expression |
EXP |
Clozapine affects the expression of DPF1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 7:29,003,366...29,017,017
Ensembl chr 7:29,003,376...29,017,668
|
|
G |
Dpp3 |
dipeptidylpeptidase 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in decreased expression of DPP3 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:4,957,257...4,978,315
Ensembl chr19:4,957,257...4,978,315
|
|
G |
Dpysl3 |
dihydropyrimidinase-like 3 |
decreases expression |
ISO |
Clozapine results in decreased expression of DPYSL3 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:43,454,044...43,571,354
Ensembl chr18:43,454,049...43,571,351
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
decreases expression |
ISO |
Clozapine results in decreased expression of DPYSL4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:138,665,917...138,681,711
Ensembl chr 7:138,665,917...138,682,620
|
|
G |
Dr1 |
down-regulator of transcription 1 |
decreases expression |
ISO |
Clozapine results in decreased expression of DR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:108,416,763...108,428,387
Ensembl chr 5:108,416,763...108,428,392
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding decreases expression affects response to substance |
ISO EXP |
Clozapine binds to DRD1 protein Clozapine results in decreased expression of DRD1 mRNA Clozapine analog binds to DRD1 protein DRD1 gene polymorphism affects the susceptibility to Clozapine; DRD1 protein affects the susceptibility to Clozapine |
CTD |
PMID:1352677 PMID:9723970 PMID:11997696 PMID:17092969 PMID:17266109 |
|
NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions affects binding affects response to substance decreases expression increases response to substance |
ISO EXP |
[Clozapine co-treated with DRD2 gene polymorphism] results in increased secretion of PRL protein Clozapine binds to DRD2 protein DRD2 protein affects the susceptibility to Clozapine Clozapine results in decreased expression of DRD2 mRNA Clozapine analog binds to DRD2 protein; Clozapine binds to DRD2 protein [Clozapine binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; Bromocriptine promotes the reaction [Clozapine results in decreased expression of DRD2 mRNA]; Clozapine binds to and results in decreased activity of DRD2 protein; Clozapine promotes the reaction [Dopamine binds to DRD2 protein]; DRD2 protein affects the reaction [Clozapine results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Clozapine results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Clozapine results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Clozapine results in increased expression of GSK3B protein] [Clozapine co-treated with Bromocriptine] results in decreased expression of DRD2 mRNA Clozapine binds to DRD2 protein alternative form DRD2 gene SNP results in increased susceptibility to Clozapine DRD2 gene affects the susceptibility to Clozapine; DRD2 gene polymorphism affects the susceptibility to Clozapine |
CTD |
PMID:1352677 PMID:9723970 PMID:11997696 PMID:12476322 PMID:15286066 PMID:15716360 PMID:15781964 PMID:15830237 PMID:16033416 PMID:16144542 PMID:16278074 PMID:17266109 PMID:20375926 More...
|
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Drd3 |
dopamine receptor D3 |
affects response to substance multiple interactions decreases response to substance |
ISO EXP |
DRD3 protein affects the susceptibility to Clozapine DRD3 protein affects the reaction [Clozapine results in increased expression of FOSB protein alternative form] DRD3 gene polymorphism results in decreased susceptibility to Clozapine |
CTD |
PMID:15579174 PMID:20029384 |
|
NCBI chr16:43,574,285...43,646,353
Ensembl chr16:43,574,389...43,643,295
|
|
G |
Drd4 |
dopamine receptor D4 |
affects binding multiple interactions affects response to substance |
ISO |
Clozapine binds to DRD4 protein Clozapine binds to Drd4 protein Clozapine inhibits the reaction [Dopamine results in increased activity of DRD4 protein] Clozapine analog binds to DRD4 protein DRD4 gene polymorphism affects the susceptibility to Clozapine |
CTD RGD |
PMID:11997696 PMID:16223700 PMID:31323226 PMID:8078498 |
RGD:7248459 |
NCBI chr 7:140,871,931...140,874,868
Ensembl chr 7:140,871,919...140,876,377
|
|
G |
Drp2 |
dystrophin related protein 2 |
increases expression |
ISO |
Clozapine results in increased expression of DRP2 mRNA alternative form |
CTD |
PMID:16715494 |
|
NCBI chr X:133,304,868...133,357,323
Ensembl chr X:133,305,300...133,357,322
|
|
G |
Dtnbp1 |
dystrobrevin binding protein 1 |
increases response to substance affects response to substance |
ISO |
DTNBP1 gene polymorphism results in increased susceptibility to Clozapine DTNBP1 protein affects the susceptibility to Clozapine |
CTD |
PMID:19369910 |
|
NCBI chr13:45,075,552...45,155,614
Ensembl chr13:45,075,551...45,155,623
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
decreases expression |
ISO |
Clozapine results in decreased expression of DUSP1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression |
ISO |
Clozapine results in decreased expression of DUSP6 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:99,098,676...99,103,351
Ensembl chr10:99,099,093...99,103,351
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
increases expression multiple interactions |
ISO |
Clozapine results in increased expression of DVL3 protein DRD2 protein affects the reaction [Clozapine results in increased expression of DVL3 protein] |
CTD |
PMID:16144542 |
|
NCBI chr16:20,335,694...20,352,763
Ensembl chr16:20,335,732...20,352,760
|
|
G |
Dync1li1 |
dynein cytoplasmic 1 light intermediate chain 1 |
decreases expression |
ISO |
Clozapine results in decreased expression of DYNC1LI1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:114,517,899...114,552,856
Ensembl chr 9:114,517,858...114,553,370
|
|
G |
Dync1li2 |
dynein, cytoplasmic 1 light intermediate chain 2 |
decreases expression |
ISO |
Clozapine results in decreased expression of DYNC1LI2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:105,144,306...105,170,415
Ensembl chr 8:105,144,312...105,169,679
|
|
G |
Edc4 |
enhancer of mRNA decapping 4 |
increases expression |
ISO |
Clozapine results in increased expression of EDC4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:106,607,506...106,619,857
Ensembl chr 8:106,607,513...106,621,540
|
|
G |
Eef1a2 |
eukaryotic translation elongation factor 1 alpha 2 |
increases expression |
ISO |
Clozapine results in increased expression of EEF1A2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:180,783,551...180,798,808
Ensembl chr 2:180,789,446...180,798,807
|
|
G |
Eef1d |
eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) |
decreases expression |
ISO |
Clozapine results in decreased expression of EEF1D protein |
CTD |
PMID:34122009 |
|
NCBI chr15:75,766,643...75,781,425
Ensembl chr15:75,766,054...75,781,405
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
ISO |
Clozapine results in decreased expression of EGR1 mRNA; Clozapine results in decreased expression of EGR1 protein |
CTD |
PMID:17028028 PMID:18208916 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Egr2 |
early growth response 2 |
affects expression decreases expression |
EXP ISO |
Clozapine affects the expression of EGR2 mRNA Clozapine results in decreased expression of EGR2 protein |
CTD |
PMID:17028028 PMID:19401217 |
|
NCBI chr10:67,370,334...67,383,354
Ensembl chr10:67,371,305...67,378,018
|
|
G |
Egr3 |
early growth response 3 |
affects response to substance |
EXP |
EGR3 protein affects the susceptibility to Clozapine |
CTD |
PMID:17637609 |
|
NCBI chr14:70,314,766...70,320,062
Ensembl chr14:70,314,652...70,320,063
|
|
G |
Eif2s3x |
eukaryotic translation initiation factor 2, subunit 3, structural gene X-linked |
increases expression |
ISO |
Clozapine results in increased expression of EIF2S3 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:93,232,315...93,256,257
Ensembl chr X:93,232,313...93,256,468
|
|
G |
Eif3c |
eukaryotic translation initiation factor 3, subunit C |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in decreased expression of EIF3C protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:126,146,083...126,165,538
Ensembl chr 7:126,145,627...126,165,583
|
|
G |
Eif3j1 |
eukaryotic translation initiation factor 3, subunit J1 |
increases expression |
ISO |
Clozapine results in increased expression of EIF3J protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:121,859,061...121,884,113
Ensembl chr 2:121,859,027...121,887,079
|
|
G |
Eif3m |
eukaryotic translation initiation factor 3, subunit M |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in increased expression of EIF3M protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:104,830,001...104,847,372
Ensembl chr 2:104,830,001...104,847,425
|
|
G |
Eif4a3 |
eukaryotic translation initiation factor 4A3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in decreased expression of EIF4A3 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:119,179,189...119,190,869
Ensembl chr11:119,179,189...119,190,915
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
[Cuprizone co-treated with Clozapine] results in increased expression of EIF4E protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:138,231,952...138,265,457
Ensembl chr 3:138,231,940...138,265,457
|
|
G |
Eif5b |
eukaryotic translation initiation factor 5B |
increases expression |
ISO |
Clozapine results in increased expression of EIF5B protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:38,037,091...38,094,660
Ensembl chr 1:38,037,091...38,094,660
|
|
G |
Eif6 |
eukaryotic translation initiation factor 6 |
decreases expression |
ISO |
Clozapine results in decreased expression of EIF6 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:155,661,757...155,668,845
Ensembl chr 2:155,661,752...155,668,845
|
|
G |
Elk1 |
ELK1, member of ETS oncogene family |
decreases phosphorylation |
EXP |
Clozapine results in decreased phosphorylation of ELK1 protein |
CTD |
PMID:12871586 |
|
NCBI chr X:20,799,634...20,816,847
Ensembl chr X:20,799,634...20,816,847
|
|
G |
Eno1 |
enolase 1, alpha non-neuron |
increases expression |
ISO |
Clozapine results in increased expression of ENO1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
|
|
G |
Eno3 |
enolase 3, beta muscle |
increases expression |
ISO |
Clozapine results in increased expression of ENO3 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:70,543,973...70,553,339
Ensembl chr11:70,548,028...70,553,339
|
|
G |
Epha7 |
Eph receptor A7 |
increases expression |
EXP |
Clozapine results in increased expression of EPHA7 mRNA |
CTD |
PMID:17266109 |
|
NCBI chr 4:28,811,840...28,969,391
Ensembl chr 4:28,813,131...28,967,499
|
|
G |
Ephb3 |
Eph | |